Herbert Y. Meltzer, M.D. - Publications

Affiliations: 
Northwestern University Feinberg School of Medicine, Chicago, IL, United States 

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Rajagopal L, Mahjour S, Huang M, Ryan CA, Elzokaky A, Csakai AJ, Orr MJ, Scheidt K, Meltzer HY. NU-1223, a simplified analog of alstonine, with 5-HTR agonist-like activity, rescues memory deficit and positive and negative symptoms in subchronic phencyclidine mouse model of schizophrenia. Behavioural Brain Research. 114614. PMID 37572758 DOI: 10.1016/j.bbr.2023.114614  0.342
2021 Meltzer HY, Gadaleta E. Contrasting Typical and Atypical Antipsychotic Drugs. Focus (American Psychiatric Publishing). 19: 3-13. PMID 34483761 DOI: 10.1176/appi.focus.20200051  0.349
2020 Baltzersen OB, Meltzer HY, Frokjaer VG, Raghava JM, Baandrup L, Fagerlund B, Larsson HBW, Fibiger HC, Glenthøj BY, Knudsen GM, Ebdrup BH. Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol. Frontiers in Pharmacology. 11: 591. PMID 32425802 DOI: 10.3389/Fphar.2020.00591  0.403
2020 Maes MS, Lu JY, Tiwari AK, Freeman N, de Luca V, Müller DJ, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL, Zai CC. Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia. Drug Development Research. PMID 32394511 DOI: 10.1002/Ddr.21681  0.399
2020 Meltzer HY, Share DB, Jayathilake K, Salomon RM, Lee MA. Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology. 40: 240-249. PMID 32332459 DOI: 10.1097/Jcp.0000000000001205  0.385
2020 Huang M, He W, Rajagopal L, Kudwa A, Grigoriadis DE, Meltzer HY. Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action. Pharmacology, Biochemistry, and Behavior. 172872. PMID 32084491 DOI: 10.1016/J.Pbb.2020.172872  0.332
2019 Karpouzian-Rogers T, Stocks J, Meltzer HY, Reilly JL. The effect of high vs. low dose lurasidone on eye movement biomarkers of prefrontal abilities in treatment-resistant schizophrenia. Schizophrenia Research. PMID 31706786 DOI: 10.1016/J.Schres.2019.10.008  0.335
2019 Yoshikawa A, Li J, Meltzer HY. A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs. The Pharmacogenomics Journal. PMID 31636356 DOI: 10.1038/S41397-019-0101-5  0.344
2019 Huang M, He W, Kiss B, Farkas B, Adham N, Meltzer HY. The Role of Dopamine D3 Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens. The Journal of Pharmacology and Experimental Therapeutics. PMID 31511365 DOI: 10.1124/Jpet.119.259879  0.369
2019 Maciukiewicz M, Tiwari AK, Zai CC, Gorbovskaya I, Laughlin CP, Nurmi EL, Liebermann JA, Meltzer HY, Kennedy JL, Müller DJ. Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans. Schizophrenia Research. PMID 31447353 DOI: 10.1016/J.Schres.2019.07.022  0.308
2019 Alkelai A, Greenbaum L, Heinzen EL, Baugh EH, Teitelbaum A, Zhu X, Strous RD, Tatarskyy P, Zai CC, Tiwari AK, Tampakeras M, Freeman N, Müller DJ, Voineskos AN, Lieberman JA, ... ... Meltzer HY, et al. New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 109659. PMID 31153890 DOI: 10.1016/J.Pnpbp.2019.109659  0.33
2019 Li J, Hashimoto H, Meltzer HY. Association of Serotonin Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia. Frontiers in Psychiatry. 10: 58. PMID 30828307 DOI: 10.3389/Fpsyt.2019.00058  0.386
2019 Yoshida K, Maciukiewicz M, Marshe VS, Tiwari AK, Brandl EJ, Liebermann JA, Meltzer HY, Kennedy JL, Mueller DJ. 59 Polygenic Risk Scores Analyses In Antipsychotic-Induced Weight Gain European Neuropsychopharmacology. 29. DOI: 10.1016/J.Euroneuro.2019.07.200  0.308
2019 Hauschild A, Maciukiewicz M, Tiwari A, Zai C, Liebermann JA, Meltzer H, Kennedy JL, Mueller D. F24Systems Biology Approach To Evaluate Genetic Factors Of Antipsychotic Induced Weight Gain In Patients With Schizophrenia European Neuropsychopharmacology. 29. DOI: 10.1016/J.Euroneuro.2018.08.104  0.339
2019 Meltzer H. S187. Subchronic PCP Treatment in Mice Recapitulates Synaptic Proteomic Changes in Schizophrenia Cortex via Effects on CAMK2 and Microtubules and Rescue by Atypical Antipsychotic, Lurasidone Biological Psychiatry. 85: S369. DOI: 10.1016/J.Biopsych.2019.03.938  0.335
2018 Meltzer HY, Rajagopal L, Matrisciano F, Hao J, Svensson KA, Huang M. The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice. Behavioural Brain Research. PMID 30521930 DOI: 10.1016/J.Bbr.2018.12.006  0.339
2018 Zai CC, Lee FH, Tiwari AK, Lu JY, de Luca V, Maes MS, Herbert D, Shahmirian A, Cheema SY, Zai GC, Atukuri A, Sherman M, Shaikh SA, Tampakeras M, Freeman N, ... ... Meltzer HY, et al. Investigation of the Gene in Tardive Dyskinesia - New Data and Meta-Analysis. Frontiers in Pharmacology. 9: 974. PMID 30283332 DOI: 10.3389/Fphar.2018.00974  0.312
2018 Maciukiewicz M, Gorbovskaya I, Tiwari AK, Zai CC, Freeman N, Meltzer HY, Kennedy JL, Müller DJ. Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 30229349 DOI: 10.1007/S00702-018-1921-1  0.326
2018 Lu JY, Tiwari AK, Zai GC, Rastogi A, Shaikh SA, Mueller DJ, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Wong AHC, Kennedy JL, Zai CC. Association study of Disrupted-In-Schizophrenia-1 Gene variants and Tardive Dyskinesia. Neuroscience Letters. PMID 30118782 DOI: 10.1016/J.Neulet.2018.08.007  0.382
2018 Rajagopal L, Huang M, Michael E, Kwon S, Meltzer HY. TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABA receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30093697 DOI: 10.1038/S41386-018-0160-3  0.382
2018 Huang M, Kwon S, Rajagopal L, He W, Meltzer HY. 5-HT parital agonism and 5-HT antagonism restore episodic memory in subchronic phencyclidine-treated mice: role of brain glutamate, dopamine, acetylcholine and GABA. Psychopharmacology. PMID 30066135 DOI: 10.1007/S00213-018-4972-Y  0.372
2018 Meltzer HY, Sim MY, Anderson A, Cannistraci C, Jayathilake K, Share DB, Lee M. A within-subject consideration of the psychotic spectrum disorder concept in a patient in remission associated with cortical gray matter recovery. Cns Neuroscience & Therapeutics. 24: 641-651. PMID 29898284 DOI: 10.1111/Cns.12986  0.308
2018 Rajagopal L, Soni D, Meltzer HY. Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction. Behavioural Brain Research. PMID 29763637 DOI: 10.1016/J.Bbr.2018.05.005  0.362
2018 Li J, Loebel A, Meltzer HY. Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials. Schizophrenia Research. PMID 29730043 DOI: 10.1016/J.Schres.2018.04.006  0.325
2018 Maciukiewicz M, Tiwari A, Goncalves V, Zai C, Brandl E, Freeman N, Lieberman J, Meltzer H, Laughlin C, Nurmi E, Kennedy J, Mueller D. F1. GENOME-WIDE ASSOCIATION STUDIES SUGGESTED ASSOCIATION BETWEEN DGKB AND ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN EUROPEANS AND AFRICAN AMERICANS Schizophrenia Bulletin. 44: S218-S218. DOI: 10.1093/Schbul/Sby017.532  0.316
2017 Neugebauer NM, Miyauchi M, Sato T, Tadano J, Akal H, Ardehali H, Meltzer HY. Hippocampal GABAA antagonism reverses the novel object recognition deficit in sub-chronic phencyclidine-treated rats. Behavioural Brain Research. PMID 29289597 DOI: 10.1016/J.Bbr.2017.12.033  0.318
2017 Miyauchi M, Neugebauer NM, Sato T, Ardehali H, Meltzer HY. Muscarinic receptor signaling contributes to atypical antipsychotic drug reversal of the phencyclidine-induced deficit in novel object recognition in rats. Journal of Psychopharmacology (Oxford, England). 269881117731278. PMID 28946779 DOI: 10.1177/0269881117731278  0.36
2017 Meltzer HY. New Trends in the Treatment of Schizophrenia. Cns & Neurological Disorders Drug Targets. PMID 28758583 DOI: 10.2174/1871527316666170728165355  0.338
2017 Li J, Yoshikawa A, Meltzer HY. Replication of rs300774, a genetic biomarker near ACP1, associated with suicide attempts in patients with schizophrenia: Relation to brain cholesterol biosynthesis. Journal of Psychiatric Research. 94: 54-61. PMID 28668716 DOI: 10.1016/J.Jpsychires.2017.06.005  0.309
2017 Rodríguez G, Neugebauer NM, Yao KL, Meltzer HY, Csernansky JG, Dong H. Δ9-tetrahydrocannabinol (Δ9-THC) administration after neonatal exposure to phencyclidine potentiates schizophrenia-related behavioral phenotypes in mice. Pharmacology, Biochemistry, and Behavior. PMID 28648819 DOI: 10.1016/J.Pbb.2017.06.010  0.346
2017 Zai CC, Tiwari AK, Chowdhury NI, Brandl EJ, Shaikh SA, Freeman N, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain. Neuropsychobiology. 74: 169-175. PMID 28531893 DOI: 10.1159/000457903  0.363
2017 Huang M, Kwon S, He W, Meltzer HY. Neurochemical arguments for the use of dopamine D4 receptor stimulation to improve cognitive impairment associated with schizophrenia. Pharmacology, Biochemistry, and Behavior. PMID 28455126 DOI: 10.1016/J.Pbb.2017.04.010  0.386
2017 Rajagopal L, Kwon S, Huang M, Michael E, Bhat L, Cantillon M, Meltzer HY. RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia. Behavioural Brain Research. PMID 28373127 DOI: 10.1016/J.Bbr.2017.02.036  0.409
2017 Miyauchi M, Neugebauer NM, Meltzer HY. Dopamine D4 receptor stimulation contributes to novel object recognition: Relevance to cognitive impairment in schizophrenia. Journal of Psychopharmacology (Oxford, England). 31: 442-452. PMID 28347261 DOI: 10.1177/0269881117693746  0.332
2017 Pogorelov VM, Rodriguiz RM, Cheng J, Huang M, Schmerberg CM, Meltzer HY, Roth BL, Kozikowski AP, Wetsel WC. 5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28294132 DOI: 10.1038/Npp.2017.52  0.413
2017 Lanning R, Lett TA, Tiwari AK, Brandl EJ, de Luca V, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Müller DJ, Remington G, Kennedy JL, Zai CC. Association study between the neurexin-1 gene and tardive dyskinesia. Human Psychopharmacology. 32. PMID 28120489 DOI: 10.1002/Hup.2568  0.304
2017 Chen C, Tiwari A, Zai C, Tylor D, Potkin S, Meltzer H, Lieberman J, Mueller D, Kennedy J. SU3. Preliminary Study for Association of Genome-Wide Significant Glutamate Receptor Schizophrenia Risk Variants With Clozapine Response Schizophrenia Bulletin. 43: S161-S162. DOI: 10.1093/Schbul/Sbx024.002  0.36
2017 Kennedy JL, Huang E, Tiwari AK, Zai C, Gonçalves V, Potkin S, Lieberman J, Meltzer H. Preliminary Model For The Genetic Prediction Of Clozapine Response European Neuropsychopharmacology. 27: S456. DOI: 10.1016/J.Euroneuro.2016.09.526  0.34
2017 Kanji S, Maciukiewicz M, Tiwari AK, Goncalves VF, Zai C, Brandl E, Freeman N, Liebermann JA, Meltzer HY, Kennedy JL, Mueller DJ. 227. Validation Study in Two Genome-Wide Significant Risk Variants for Antipsychotic-Induced Weight Gain Biological Psychiatry. 81. DOI: 10.1016/J.Biopsych.2017.02.241  0.309
2016 Wang JR, Sun PH, Ren ZX, Meltzer HY, Zhen XC. GSK-3β Interacts with Dopamine D1 Receptor to Regulate Receptor Function: Implication for Prefrontal Cortical D1 Receptor Dysfunction in Schizophrenia. Cns Neuroscience & Therapeutics. PMID 27996211 DOI: 10.1111/Cns.12664  0.371
2016 Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, ... ... Meltzer H, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. The American Journal of Psychiatry. appiajp201616050503. PMID 27919182 DOI: 10.1176/Appi.Ajp.2016.16050503  0.317
2016 Tiwari AK, Zhang D, Pouget JG, Zai CC, Chowdhury NI, Brandl EJ, Qin L, Freeman N, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Impact of Histamine Receptors H1 and H3 Polymorphisms on Antipsychotic-Induced Weight Gain. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 1-19. PMID 27855565 DOI: 10.1080/15622975.2016.1262061  0.3
2016 Brandl EJ, Lett TA, Chowdhury NI, Tiwari AK, Bakanidze G, Meltzer HY, Potkin SG, Lieberman JA, Kennedy JL, Müller DJ. The role of the ITIH3 rs2535629 variant in antipsychotic response. Schizophrenia Research. PMID 27396837 DOI: 10.1016/J.Schres.2016.06.032  0.331
2016 Alshammari TK, Alshammari MA, Nenov MN, Hoxha E, Cambiaghi M, Marcinno A, James TF, Singh P, Labate D, Li J, Meltzer HY, Sacchetti B, Tempia F, Laezza F. Genetic deletion of fibroblast growth factor 14 recapitulates phenotypic alterations underlying cognitive impairment associated with schizophrenia. Translational Psychiatry. 6: e806. PMID 27163207 DOI: 10.1038/Tp.2016.66  0.31
2016 Taylor DL, Tiwari AK, Lieberman JA, Potkin SG, Meltzer HY, Knight J, Remington G, Müller DJ, Kennedy JL. Genetic association analysis of N-methyl-d-aspartate receptor subunit gene GRIN2B and clinical response to clozapine. Human Psychopharmacology. PMID 26876050 DOI: 10.1002/Hup.2519  0.379
2016 Huang E, Zai CC, Lisoway A, Maciukiewicz M, Felsky D, Tiwari AK, Bishop JR, Ikeda M, Molero P, Ortuno F, Porcelli S, Samochowiec J, Mierzejewski P, Gao S, Crespo-Facorro B, ... ... Meltzer HY, et al. Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). PMID 26745992 DOI: 10.1093/Ijnp/Pyv132  0.357
2016 Huang E, Maciukiewicz M, Zai CC, Tiwari AK, Li J, Potkin SG, Lieberman JA, Meltzer HY, Müller DJ, Kennedy JL. Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response. Pharmacogenomics. 17: 103-9. PMID 26666695 DOI: 10.2217/Pgs.15.155  0.353
2016 Nomura T, Oyamada Y, Fernandes HB, Remmers CL, Xu J, Meltzer HY, Contractor A. Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus. Neuropharmacology. 100: 90-7. PMID 25937215 DOI: 10.1016/J.Neuropharm.2015.04.012  0.302
2016 Kim SI, Lee MA, Jayathilake K, Meltzer HY. PM493. Interactions of tardive dyskinesia with cognitive function in patients with schizophrenia: worsening of working memory with clozapine treatment. The International Journal of Neuropsychopharmacology. 19: 79-80. DOI: 10.1093/Ijnp/Pyw041.493  0.353
2015 Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, Németh G, Meltzer HY. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. The Journal of Clinical Psychiatry. 76: e1574-e1582. PMID 26717533 DOI: 10.4088/Jcp.15M09997  0.331
2015 Rajagopal L, Burgdorf JS, Moskal JR, Meltzer HY. GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice. Behavioural Brain Research. PMID 26632337 DOI: 10.1016/J.Bbr.2015.10.060  0.323
2015 Rajagopal L, Massey BW, Michael E, Meltzer HY. Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice. Psychopharmacology. PMID 26558619 DOI: 10.1007/S00213-015-4137-1  0.358
2015 Miyauchi M, Neugebauer NM, Oyamada Y, Meltzer HY. Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition. Behavioural Brain Research. PMID 26519556 DOI: 10.1016/J.Bbr.2015.10.044  0.338
2015 Tiwari AK, Brandl EJ, Zai CC, Goncalves VF, Chowdhury NI, Freeman N, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 1-9. PMID 26447462 DOI: 10.3109/15622975.2015.1076173  0.312
2015 Huang M, Kwon S, Oyamada Y, Rajagopal L, Miyauchi M, Meltzer HY. Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement. Pharmacology, Biochemistry, and Behavior. 138: 49-57. PMID 26383990 DOI: 10.1016/J.Pbb.2015.09.011  0.362
2015 Horiguchi M, Miyauchi M, Neugebauer NM, Oyamada Y, Meltzer HY. Prolonged reversal of the phencyclidine-induced impairment in novel object recognition by a serotonin (5-HT)1A-dependent mechanism. Behavioural Brain Research. PMID 26342283 DOI: 10.1016/J.Bbr.2015.08.040  0.354
2015 Meltzer HY, Risinger R, Nasrallah HA, Du Y, Zummo J, Corey L, Bose A, Stankovic S, Silverman BL, Ehrich EW. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. The Journal of Clinical Psychiatry. 76: 1085-1090. PMID 26114240 DOI: 10.4088/Jcp.14M09741  0.356
2015 Meltzer HY. Attention Must Be Paid: The Association of Plasma Clozapine/NDMC Ratio With Working Memory. The American Journal of Psychiatry. 172: 502-4. PMID 26029799 DOI: 10.1176/Appi.Ajp.2015.15030338  0.308
2015 Bonaccorso S, Sodhi M, Li J, Bobo WV, Chen Y, Tumuklu M, Theleritis C, Jayathilake K, Meltzer HY. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. Bipolar Disorders. PMID 25874530 DOI: 10.1111/Bdi.12294  0.355
2015 Lee MA, Jayathilake K, Sim MY, Meltzer HY. Decreased serotonin2C receptor responses in male patients with schizophrenia. Psychiatry Research. 226: 308-15. PMID 25650049 DOI: 10.1016/J.Psychres.2015.01.007  0.427
2015 Pouget JG, Gonçalves VF, Nurmi EL, P Laughlin C, Mallya KS, McCracken JT, Aman MG, McDougle CJ, Scahill L, Misener VL, Tiwari AK, Zai CC, Brandl EJ, Felsky D, Leung AQ, ... ... Meltzer HY, et al. Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. Pharmacogenomics. 16: 5-22. PMID 25560467 DOI: 10.2217/Pgs.14.158  0.429
2015 Zai CC, Tiwari AK, Chowdhury NI, Brandl EJ, Shaikh SA, Freeman N, Lieberman JA, Meltzer HY, Müller DJ, Kennedy JL. Association study of GABAA α2 receptor subunit gene variants in antipsychotic-associated weight gain. Journal of Clinical Psychopharmacology. 35: 7-12. PMID 25514066 DOI: 10.1097/Jcp.0000000000000261  0.428
2015 Oyamada Y, Horiguchi M, Rajagopal L, Miyauchi M, Meltzer HY. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. Behavioural Brain Research. 285: 165-75. PMID 25448429 DOI: 10.1016/J.Bbr.2014.09.040  0.402
2015 Yamasaki A, Kasai A, Toi A, Kurita M, Kimoto S, Hayata-Takano A, Nakazawa T, Nagayasu K, Shintani N, Hashimoto R, Ito A, Meltzer HY, Ago Y, Waschek JA, Onaka Y, et al. Identification of the role of bone morphogenetic protein (BMP) and transforming growth factor-β (TGF-β) signaling in the trajectory of serotonergic differentiation in a rapid assay in mouse embryonic stem cells in vitro. Journal of Neurochemistry. 132: 418-28. PMID 25421849 DOI: 10.1111/Jnc.12999  0.305
2015 Hagino Y, Kasai S, Fujita M, Setogawa S, Yamaura H, Yanagihara D, Hashimoto M, Kobayashi K, Meltzer HY, Ikeda K. Involvement of cholinergic system in hyperactivity in dopamine-deficient mice. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 1141-50. PMID 25367503 DOI: 10.1038/Npp.2014.295  0.357
2015 Brandl EJ, Chowdhury NI, Tiwari AK, Lett TA, Meltzer HY, Kennedy JL, Müller DJ. Genetic variation in CYP3A43 is associated with response to antipsychotic medication. Journal of Neural Transmission (Vienna, Austria : 1996). 122: 29-34. PMID 25150845 DOI: 10.1007/S00702-014-1298-8  0.383
2015 Meltzer HY. Pharmacotherapy of cognition in schizophrenia Current Opinion in Behavioral Sciences. 4: 115-121. DOI: 10.1016/J.Cobeha.2015.04.009  0.373
2014 Li J, Meltzer HY. A genetic locus in 7p12.2 associated with treatment resistant schizophrenia. Schizophrenia Research. 159: 333-9. PMID 25223841 DOI: 10.1016/J.Schres.2014.08.018  0.433
2014 Brandl EJ, Tiwari AK, Zai CC, Chowdhury NI, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain. Psychiatry Research. 219: 255-60. PMID 24953421 DOI: 10.1016/J.Psychres.2014.05.031  0.412
2014 Huang M, Felix AR, Flood DG, Bhuvaneswaran C, Hilt D, Koenig G, Meltzer HY. The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology. 231: 4541-51. PMID 24810107 DOI: 10.1007/S00213-014-3596-0  0.393
2014 Gagliano SA, Tiwari AK, Freeman N, Lieberman JA, Meltzer HY, Kennedy JL, Knight J, Müller DJ. Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain. Human Psychopharmacology. 29: 330-5. PMID 24737441 DOI: 10.1002/Hup.2407  0.392
2014 Kao AC, Rojnic Kuzman M, Tiwari AK, Zivkovic MV, Chowdhury NI, Medved V, Kekin I, Zai CC, Lieberman JA, Meltzer HY, Bozina T, Bozina N, Kennedy JL, Sertic J, Müller DJ. Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. Journal of Psychiatric Research. 54: 36-42. PMID 24725652 DOI: 10.1016/J.Jpsychires.2014.03.012  0.372
2014 Meltzer HY, Lindenmayer JP, Kwentus J, Share DB, Johnson R, Jayathilake K. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. Schizophrenia Research. 154: 14-22. PMID 24630262 DOI: 10.1016/J.Schres.2014.02.015  0.386
2014 Brandl EJ, Tiwari AK, Chowdhury NI, Zai CC, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. Pharmacogenomics. 15: 423-31. PMID 24624910 DOI: 10.2217/Pgs.13.247  0.361
2014 Chowdhury NI, Souza RP, Tiwari AK, Brandl EJ, Sicard M, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ. Investigation of melanocortin system gene variants in antipsychotic-induced weight gain. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 15: 251-8. PMID 24564533 DOI: 10.3109/15622975.2013.858827  0.394
2014 Schmid CL, Streicher JM, Meltzer HY, Bohn LM. Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a βarrestin2-independent activation of Akt. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 1902-13. PMID 24531562 DOI: 10.1038/Npp.2014.38  0.366
2014 Shing EC, Tiwari AK, Brandl EJ, Zai CC, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Fat mass- and obesity-associated (FTO) gene and antipsychotic-induced weight gain: an association study. Neuropsychobiology. 69: 59-63. PMID 24481458 DOI: 10.1159/000356231  0.304
2014 Sumiyoshi C, Ertugrul A, Anil YaÄŸcıoÄŸlu AE, Roy A, Jayathilake K, Milby A, Meltzer HY, Sumiyoshi T. Language-dependent performance on the letter fluency task in patients with schizophrenia. Schizophrenia Research. 152: 421-9. PMID 24444749 DOI: 10.1016/J.Schres.2013.12.009  0.34
2014 Rajagopal L, Massey BW, Huang M, Oyamada Y, Meltzer HY. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Current Pharmaceutical Design. 20: 5104-14. PMID 24345269 DOI: 10.2174/1381612819666131216114240  0.423
2014 Huang M, Felix AR, Kwon S, Lowe D, Wallace T, Santarelli L, Meltzer HY. The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release. Psychopharmacology. 231: 2199-210. PMID 24317442 DOI: 10.1007/S00213-013-3373-5  0.402
2014 Kishi T, Meltzer HY, Matsuda Y, Iwata N. Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis. Psychological Medicine. 44: 2255-69. PMID 24262766 DOI: 10.1017/S0033291713002857  0.317
2014 Gonçalves VF, Zai CC, Tiwari AK, Brandl EJ, Derkach A, Meltzer HY, Lieberman JA, Müller DJ, Sun L, Kennedy JL. A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 1347-54. PMID 24196945 DOI: 10.1038/Npp.2013.312  0.416
2014 Huang M, Panos JJ, Kwon S, Oyamada Y, Rajagopal L, Meltzer HY. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism. Journal of Neurochemistry. 128: 938-49. PMID 24164459 DOI: 10.1111/Jnc.12512  0.688
2014 Agarwal G, Pirigyi M, Meltzer H. Schizophrenia and Suicide: Treatment Optimization Current Treatment Options in Psychiatry. 1: 149-162. DOI: 10.1007/S40501-014-0012-7  0.345
2013 Meltzer HY, Roth BL. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. The Journal of Clinical Investigation. 123: 4986-91. PMID 24292660 DOI: 10.1172/Jci70678  0.373
2013 Meltzer HY, Rajagopal L, Huang M, Oyamada Y, Kwon S, Horiguchi M. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 16: 2181-94. PMID 24099265 DOI: 10.1017/S1461145713000928  0.486
2013 Zai CC, Tiwari AK, Mazzoco M, de Luca V, Müller DJ, Shaikh SA, Lohoff FW, Freeman N, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. Journal of Psychiatric Research. 47: 1760-5. PMID 24018103 DOI: 10.1016/J.Jpsychires.2013.07.025  0.424
2013 Chan LF, Zai C, Monda M, Potkin S, Kennedy JL, Remington G, Lieberman J, Meltzer HY, De Luca V. Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics. 14: 1273-81. PMID 23930674 DOI: 10.2217/Pgs.13.127  0.349
2013 Kishi T, Meltzer HY, Iwata N. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 16: 1259-66. PMID 23551924 DOI: 10.1017/S1461145713000151  0.389
2013 Horiguchi M, Meltzer HY. Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: role of indirect 5-HT(1A) partial agonism. Behavioural Brain Research. 247: 158-64. PMID 23538066 DOI: 10.1016/J.Bbr.2013.03.027  0.463
2013 Lett TA, Chakravarty MM, Chakavarty MM, Felsky D, Brandl EJ, Tiwari AK, Gonçalves VF, Rajji TK, Daskalakis ZJ, Meltzer HY, Lieberman JA, Lerch JP, Mulsant BH, Kennedy JL, Voineskos AN. The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Molecular Psychiatry. 18: 443-50. PMID 23459466 DOI: 10.1038/Mp.2013.17  0.375
2013 Brandl EJ, Tiwari AK, Lett TA, Shaikh SA, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. Human Psychopharmacology. 28: 183-7. PMID 23364847 DOI: 10.1002/Hup.2288  0.417
2013 Tiwari AK, Brandl EJ, Weber C, Likhodi O, Zai CC, Hahn MK, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. Journal of Clinical Psychopharmacology. 33: 11-7. PMID 23277265 DOI: 10.1097/Jcp.0B013E31827D145A  0.427
2013 Meltzer HY. Update on typical and atypical antipsychotic drugs. Annual Review of Medicine. 64: 393-406. PMID 23020880 DOI: 10.1146/Annurev-Med-050911-161504  0.416
2013 Horiguchi M, Hannaway KE, Adelekun AE, Huang M, Jayathilake K, Meltzer HY. D(1) receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats. Behavioural Brain Research. 238: 36-43. PMID 23018127 DOI: 10.1016/J.Bbr.2012.09.030  0.443
2013 Nowrouzi B, Souza RP, Zai C, Shinkai T, Monda M, Lieberman J, Volvaka J, Meltzer HY, Kennedy JL, De Luca V. Finite mixture regression model analysis on antipsychotics induced weight gain: investigation of the role of the serotonergic genes. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 224-8. PMID 22840963 DOI: 10.1016/J.Euroneuro.2012.05.008  0.377
2013 Chowdhury NI, Tiwari AK, Souza RP, Zai CC, Shaikh SA, Chen S, Liu F, Lieberman JA, Meltzer HY, Malhotra AK, Kennedy JL, Müller DJ. Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. The Pharmacogenomics Journal. 13: 272-9. PMID 22310352 DOI: 10.1038/Tpj.2011.66  0.416
2013 Lett TA, Chakravarty MM, Felsky D, Brandl EJ, Tiwari AK, Gonçalves VF, Rajji TK, Daskalakis ZJ, Meltzer HY, Lieberman JA, Lerch JP, Mulsant BH, Kennedy JL, Voineskos AN. Erratum: The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia (Molecular Psychiatry (2013) DOI: 10.1038/mp.2013.17) Molecular Psychiatry. 18. DOI: 10.1038/Mp.2013.39  0.35
2012 Meltzer HY. Serotonergic mechanisms as targets for existing and novel antipsychotics. Handbook of Experimental Pharmacology. 87-124. PMID 23129329 DOI: 10.1007/978-3-642-25761-2_4  0.387
2012 Liu Q, Ramsey TL, Meltzer HY, Massey BW, Padmanabhan S, Brennan MD. Sulfotransferase 4A1 Haplotype 1 (SULT4A1-1) Is Associated With Decreased Hospitalization Events in Antipsychotic-Treated Patients With Schizophrenia. The Primary Care Companion For Cns Disorders. 14. PMID 23106027 DOI: 10.4088/Pcc.11M01293  0.337
2012 Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clinical Schizophrenia & Related Psychoses. 6: 134-44. PMID 23006238 DOI: 10.3371/Csrp.6.3.5  0.416
2012 Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophrenia Research. 141: 144-52. PMID 22954754 DOI: 10.1016/J.Schres.2012.07.029  0.432
2012 Need AC, McEvoy JP, Gennarelli M, Heinzen EL, Ge D, Maia JM, Shianna KV, He M, Cirulli ET, Gumbs CE, Zhao Q, Campbell CR, Hong L, Rosenquist P, Putkonen A, ... ... Meltzer HY, et al. Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia. American Journal of Human Genetics. 91: 303-12. PMID 22863191 DOI: 10.1016/J.Ajhg.2012.06.018  0.405
2012 Horiguchi M, Hannaway KE, Adelekun AE, Jayathilake K, Meltzer HY. Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 2175-83. PMID 22739469 DOI: 10.1038/Npp.2012.64  0.43
2012 Hirata Y, Zai CC, Souza RP, Lieberman JA, Meltzer HY, Kennedy JL. Association study of GRIK1 gene polymorphisms in schizophrenia: case-control and family-based studies. Human Psychopharmacology. 27: 345-51. PMID 22730074 DOI: 10.1002/Hup.2233  0.422
2012 Zai GC, Zai CC, Chowdhury NI, Tiwari AK, Souza RP, Lieberman JA, Meltzer HY, Potkin SG, Müller DJ, Kennedy JL. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 39: 96-101. PMID 22642961 DOI: 10.1016/J.Pnpbp.2012.05.014  0.423
2012 Malhotra AK, Correll CU, Chowdhury NI, Müller DJ, Gregersen PK, Lee AT, Tiwari AK, Kane JM, Fleischhacker WW, Kahn RS, Ophoff RA, Meltzer HY, Lencz T, Kennedy JL. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Archives of General Psychiatry. 69: 904-12. PMID 22566560 DOI: 10.1001/Archgenpsychiatry.2012.191  0.405
2012 Wiebelhaus JM, Vunck SA, Meltzer HY, Porter JH. Discriminative stimulus properties of N-desmethylclozapine, the major active metabolite of the atypical antipsychotic clozapine, in C57BL/6 mice. Behavioural Pharmacology. 23: 262-70. PMID 22547022 DOI: 10.1097/Fbp.0B013E3283534332  0.383
2012 Brandl EJ, Frydrychowicz C, Tiwari AK, Lett TA, Kitzrow W, Büttner S, Ehrlich S, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ, Puls I. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 38: 134-41. PMID 22426215 DOI: 10.1016/J.Pnpbp.2012.03.001  0.4
2012 Huang M, Horiguchi M, Felix AR, Meltzer HY. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport. 23: 436-40. PMID 22415605 DOI: 10.1097/Wnr.0B013E328352De40  0.463
2012 Sun J, Jayathilake K, Zhao Z, Meltzer HY. Investigating association of four gene regions (GABRB3, MAOB, PAH, and SLC6A4) with five symptoms in schizophrenia. Psychiatry Research. 198: 202-6. PMID 22414661 DOI: 10.1016/J.Psychres.2011.12.035  0.415
2012 Souza RP, Tiwari AK, Chowdhury NI, Ceddia RB, Lieberman JA, Meltzer HY, Kennedy JL, Müller DJ. Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. Journal of Psychiatric Research. 46: 462-8. PMID 22305490 DOI: 10.1016/J.Jpsychires.2012.01.010  0.408
2012 Meltzer HY, Massey BW, Horiguchi M. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Current Pharmaceutical Biotechnology. 13: 1572-86. PMID 22283753 DOI: 10.2174/138920112800784880  0.444
2012 Chen Y, Bobo WV, Watts K, Jayathilake K, Tang T, Meltzer HY. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. Journal of Psychopharmacology (Oxford, England). 26: 1201-10. PMID 22234928 DOI: 10.1177/0269881111430748  0.352
2012 Horiguchi M, Meltzer HY. The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology. 221: 205-15. PMID 22227609 DOI: 10.1007/S00213-011-2561-4  0.413
2012 Hwang R, Tiwari AK, Zai CC, Felsky D, Remington E, Wallace T, Tong RP, Souza RP, Oh G, Potkin SG, Lieberman JA, Meltzer HY, Kennedy JL. Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 37: 62-75. PMID 22203087 DOI: 10.1016/J.Pnpbp.2011.11.018  0.432
2012 Yuen EY, Li X, Wei J, Horiguchi M, Meltzer HY, Yan Z. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses. Molecular Pharmacology. 81: 113-9. PMID 22072817 DOI: 10.1124/Mol.111.076141  0.46
2012 Tiwari AK, Zai CC, Likhodi O, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Müller DJ, Kennedy JL. Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. The Pharmacogenomics Journal. 12: 260-6. PMID 21266946 DOI: 10.1038/Tpj.2010.93  0.423
2012 Müller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK, Hwang R, Likhodi O, Shaikh S, Freeman N, Arenovich T, Heinz A, Meltzer HY, Lieberman JA, Kennedy JL. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. The Pharmacogenomics Journal. 12: 156-64. PMID 20714340 DOI: 10.1038/Tpj.2010.65  0.488
2011 Lett TA, Tiwari AK, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN, Kennedy JL, Müller DJ. The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. Schizophrenia Research. 132: 121-4. PMID 21890328 DOI: 10.1016/J.Schres.2011.08.007  0.448
2011 De Luca V, Souza RP, Viggiano E, Sickert L, Teo C, Zai C, Tiwari AK, Müller DJ, Lieberman JA, Volavka J, Meltzer HY, Kennedy JL. Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain. Human Psychopharmacology. 26: 386-91. PMID 21823169 DOI: 10.1002/Hup.1219  0.426
2011 Meltzer HY, Bonaccorso S, Bobo WV, Chen Y, Jayathilake K. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. The Journal of Clinical Psychiatry. 72: 1602-10. PMID 21813074 DOI: 10.4088/Jcp.10M05997  0.331
2011 Wiebelhaus JM, Webster KA, Meltzer HY, Porter JH. The metabolites N-desmethylclozapine and N-desmethylolanzapine produce cross-tolerance to the discriminative stimulus of the atypical antipsychotic clozapine in C57BL/6 mice. Behavioural Pharmacology. 22: 458-67. PMID 21712711 DOI: 10.1097/Fbp.0B013E328348Ec4F  0.324
2011 Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. The American Journal of Psychiatry. 168: 957-67. PMID 21676992 DOI: 10.1176/Appi.Ajp.2011.10060907  0.387
2011 Bobo WV, Woodward ND, Sim MY, Jayathilake K, Meltzer HY. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial. Schizophrenia Research. 130: 106-13. PMID 21641776 DOI: 10.1016/J.Schres.2011.05.015  0.387
2011 Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. The Journal of Pharmacology and Experimental Therapeutics. 338: 605-14. PMID 21558435 DOI: 10.1124/Jpet.111.180638  0.436
2011 Jia P, Jayathilake K, Zhao Z, Meltzer HY. Association of FAS, a TNF-α receptor gene, with treatment resistant schizophrenia. Schizophrenia Research. 129: 211-2. PMID 21549565 DOI: 10.1016/J.Schres.2011.04.013  0.409
2011 Ramsey TL, Meltzer HY, Brock GN, Mehrotra B, Jayathilake K, Bobo WV, Brennan MD. Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response. Pharmacogenomics. 12: 471-80. PMID 21521020 DOI: 10.2217/Pgs.10.205  0.348
2011 Horiguchi M, Huang M, Meltzer HY. Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology. 217: 13-24. PMID 21432027 DOI: 10.1007/S00213-011-2251-2  0.47
2011 Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Current Opinion in Pharmacology. 11: 59-67. PMID 21420906 DOI: 10.1016/J.Coph.2011.02.007  0.419
2011 Souza RP, Meltzer HY, Lieberman JA, Voineskos AN, Remington G, Kennedy JL. Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective. Human Psychopharmacology. 26: 21-7. PMID 21305610 DOI: 10.1002/Hup.1161  0.418
2011 Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology. 213: 289-305. PMID 21212939 DOI: 10.1007/S00213-010-2137-8  0.391
2011 ErtuÄŸrul A, Ozdemir H, Vural A, Dalkara T, Meltzer HY, Saka E. The influence of N-desmethylclozapine and clozapine on recognition memory and BDNF expression in hippocampus. Brain Research Bulletin. 84: 144-50. PMID 21134422 DOI: 10.1016/J.Brainresbull.2010.11.014  0.405
2011 Huang M, Dai J, Meltzer HY. 5-HT(2A) and 5-HT(2C) receptor stimulation are differentially involved in the cortical dopamine efflux-Studied in 5-HT(2A) and 5-HT(2C) genetic mutant mice. European Journal of Pharmacology. 652: 40-5. PMID 21118683 DOI: 10.1016/J.Ejphar.2010.10.094  0.384
2011 Lee M, Jayathilake K, Dai J, Meltzer HY. Decreased plasma tryptophan and tryptophan/large neutral amino acid ratio in patients with neuroleptic-resistant schizophrenia: relationship to plasma cortisol concentration. Psychiatry Research. 185: 328-33. PMID 20699195 DOI: 10.1016/J.Psychres.2010.07.013  0.304
2011 Souza RP, Rosa DV, Romano-Silva MA, Zhen M, Meltzer HY, Lieberman JA, Remington G, Kennedy JL, Wong AH. Lack of association of NALCN genetic variants with schizophrenia. Psychiatry Research. 185: 450-2. PMID 20674038 DOI: 10.1016/J.Psychres.2010.07.009  0.411
2010 Sicard MN, Zai CC, Tiwari AK, Souza RP, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics. 11: 1561-71. PMID 21121776 DOI: 10.2217/Pgs.10.123  0.407
2010 Souza RP, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL. Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. Human Psychopharmacology. 25: 582-5. PMID 20860064 DOI: 10.1002/Hup.1146  0.424
2010 Tiwari AK, Rodgers JB, Sicard M, Zai CC, Likhodi O, Freeman N, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ. Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 1484-90. PMID 20732371 DOI: 10.1016/J.Pnpbp.2010.08.009  0.435
2010 Zai CC, Manchia M, De Luca V, Tiwari AK, Squassina A, Zai GC, Strauss J, Shaikh SA, Freeman N, Meltzer HY, Lieberman J, Le Foll B, Kennedy JL. Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched case-control and family based study designs. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 1412-8. PMID 20667458 DOI: 10.1016/J.Pnpbp.2010.07.019  0.42
2010 Jia P, Wang L, Meltzer HY, Zhao Z. Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophrenia Research. 122: 38-42. PMID 20659789 DOI: 10.1016/J.Schres.2010.07.001  0.366
2010 Novak G, Zai CC, Mirkhani M, Shaikh S, Vincent JB, Meltzer H, Lieberman JA, Strauss J, Lévesque D, Kennedy JL, Le Foll B. Replicated association of the NR4A3 gene with smoking behaviour in schizophrenia and in bipolar disorder. Genes, Brain, and Behavior. 9: 910-7. PMID 20659174 DOI: 10.1111/J.1601-183X.2010.00631.X  0.303
2010 Souza RP, Remington G, Chowdhury NI, Lau MK, Voineskos AN, Lieberman JA, Meltzer HY, Kennedy JL. Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20: 688-94. PMID 20605420 DOI: 10.1016/J.Euroneuro.2010.05.002  0.388
2010 Zai CC, Tiwari AK, Müller DJ, De Luca V, Shinkai T, Shaikh S, Ni X, Sibony D, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. The catechol-O-methyl-transferase gene in tardive dyskinesia. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 11: 803-12. PMID 20586531 DOI: 10.3109/15622975.2010.486043  0.398
2010 Souza RP, Ismail P, Meltzer HY, Kennedy JL. Variants in the oxytocin gene and risk for schizophrenia. Schizophrenia Research. 121: 279-80. PMID 20547038 DOI: 10.1016/J.Schres.2010.04.019  0.384
2010 Kaneda Y, Jayathilak K, Meltzer H. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. Psychiatry Research. 178: 57-62. PMID 20452677 DOI: 10.1016/J.Psychres.2009.04.001  0.354
2010 Souza RP, Remington G, Meltzer HY, Lieberman JA, Kennedy JL, Wong AH. Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia. International Clinical Psychopharmacology. 25: 264-9. PMID 20436352 DOI: 10.1016/J.Schres.2010.02.586  0.429
2010 Meltzer HY, Bobo WV, Lee MA, Cola P, Jayathilake K. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Research. 177: 286-93. PMID 20378185 DOI: 10.1016/J.Psychres.2010.02.018  0.435
2010 Tiwari AK, Zai CC, Meltzer HY, Lieberman JA, Müller DJ, Kennedy JL. Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. Human Psychopharmacology. 25: 253-9. PMID 20373477 DOI: 10.1002/Hup.1111  0.422
2010 Souza RP, de Luca V, Remington G, Lieberman JA, Meltzer HY, Kennedy JL, Wong AH. Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. Psychopharmacology. 210: 347-54. PMID 20369355 DOI: 10.1007/S00213-010-1829-4  0.381
2010 Bobo WV, Jayathilake K, Lee MA, Meltzer HY. Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics. Psychiatry Research. 176: 114-9. PMID 20199813 DOI: 10.1016/J.Psychres.2009.03.026  0.33
2010 Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 13: 793-8. PMID 20196918 DOI: 10.1017/S1461145710000167  0.367
2010 Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenetics and Genomics. 20: 274-6. PMID 20168265 DOI: 10.1097/Fpc.0B013E328337Ce3E  0.358
2010 Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, MacNeil LT, Culotti JG, Kennedy JL, Wong AH. Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. Journal of Psychiatric Research. 44: 700-6. PMID 20116071 DOI: 10.1016/J.Jpsychires.2010.01.002  0.365
2010 Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP, Batra P, Zaidi SH, Chen S, Liu F, Puls I, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 1315-24. PMID 20107430 DOI: 10.1038/Npp.2009.235  0.351
2010 Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 881-92. PMID 19907417 DOI: 10.1038/Npp.2009.176  0.384
2010 Hirata Y, Souza RP, Lieberman JA, Meltzer HY, Kennedy JL. Lack of association between HTR4 gene polymorphisms and schizophrenia in case-control and family-based samples. Psychiatry Research. 175: 176-8. PMID 19892407 DOI: 10.1016/J.Psychres.2009.08.005  0.3
2010 Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, Meltzer HY. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. The Journal of Pharmacology and Experimental Therapeutics. 332: 622-31. PMID 19864614 DOI: 10.1124/Jpet.109.156349  0.355
2010 Zai CC, Tiwari AK, Basile V, de Luca V, Müller DJ, Voineskos AN, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 50-6. PMID 19778569 DOI: 10.1016/J.Pnpbp.2009.09.020  0.324
2010 Reznik I, Kertzman S, Grinspan H, Birger M, Shlapnikov N, Kotler M, Meltzer H. YPSP01-10 - Blood cholesterol and serum creatine kinase levels in violent psychiatric patients European Psychiatry. 25: 1711. DOI: 10.1016/S0924-9338(10)71690-4  0.352
2010 Cucchiaro J, Silva R, Ogasa M, Xu J, Phillips D, Simonelli D, Kalali A, Loebel A, Meltzer H. Lurasidone In The Treatment Of Acute Schizophrenia: Results Of The Double-Blind, Placebo-Controlled Pearl 2 Trial Schizophrenia Research. 117: 493-493. DOI: 10.1016/J.Schres.2010.02.936  0.335
2010 Meltzer HY, Ranjan R. Efficacy of Novel Antipsychotic Drugs in Treatment-Refractory Schizophrenia Handbook of Experimental Pharmacology. 120: 333-357. DOI: 10.1007/978-3-642-61007-3_12  0.364
2009 Souza RP, Tampakeras M, Basile V, Shinkai T, Rosa DV, Potkin S, Meltzer HY, Lieberman JA, Romano-Silva MA, Kennedy JL. Lack of association of GPX1 and MnSOD genes with symptom severity and response to clozapine treatment in schizophrenia subjects. Human Psychopharmacology. 24: 676-9. PMID 19946932 DOI: 10.1002/Hup.1076  0.359
2009 Zai CC, Tiwari AK, King N, De Luca V, Mueller DJ, Shaikh S, Wong GW, Meltzer HY, Lieberman JA, Kennedy JL. Association study of the gamma-aminobutyric acid type a receptor gamma2 subunit gene with schizophrenia. Schizophrenia Research. 114: 33-8. PMID 19682861 DOI: 10.1016/J.Schres.2009.07.010  0.336
2009 Kaneda Y, Jayathilak K, Meltzer HY. Determinants of work outcome in schizophrenia and schizoaffective disorder: role of cognitive function. Psychiatry Research. 169: 178-9. PMID 19646764 DOI: 10.1016/J.Psychres.2008.08.003  0.342
2009 Bobo WV, Jayathilake K, Lee MA, Meltzer HY. Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics. Human Psychopharmacology. 24: 415-22. PMID 19551763 DOI: 10.1002/Hup.1036  0.345
2009 Li Z, Prus AJ, Dai J, Meltzer HY. Differential effects of M1 and 5-hydroxytryptamine1A receptors on atypical antipsychotic drug-induced dopamine efflux in the medial prefrontal cortex. The Journal of Pharmacology and Experimental Therapeutics. 330: 948-55. PMID 19491322 DOI: 10.1124/Jpet.109.155663  0.348
2009 Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology. 205: 119-28. PMID 19337725 DOI: 10.1007/S00213-009-1521-8  0.351
2009 Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, Dawant B, Zald D, Meltzer HY. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biological Psychiatry. 65: 1024-31. PMID 19251247 DOI: 10.1016/J.Biopsych.2008.12.029  0.319
2009 Zai CC, Tiwari AK, Basile V, De Luca V, Müller DJ, King N, Voineskos AN, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. The Pharmacogenomics Journal. 9: 168-74. PMID 19238168 DOI: 10.1038/Tpj.2009.2  0.331
2009 Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL, Shianna KV, Yoon W, KasperaviciÅ«te D, Gennarelli M, Strittmatter WJ, Bonvicini C, Rossi G, Jayathilake K, Cola PA, ... ... Meltzer HY, et al. A genome-wide investigation of SNPs and CNVs in schizophrenia. Plos Genetics. 5: e1000373. PMID 19197363 DOI: 10.1371/Journal.Pgen.1000373  0.357
2009 Philibin SD, Walentiny DM, Vunck SA, Prus AJ, Meltzer HY, Porter JH. Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism. Psychopharmacology. 203: 303-15. PMID 18989659 DOI: 10.1007/S00213-008-1385-3  0.317
2009 Geffen Y, Nudelman A, Gil-Ad I, Rephaeli A, Huang M, Savitsky K, Klapper L, Winkler I, Meltzer HY, Weizman A. BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 19: 1-13. PMID 18757185 DOI: 10.1016/J.Euroneuro.2008.07.002  0.395
2009 Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL, Shianna KV, Yoon W, Kasperavičiūtė D, Gennarelli M, Strittmatter WJ, Bonvicini C, Rossi G, Jayathilake K, Cola PA, ... ... Meltzer HY, et al. Correction: A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia Plos Genetics. 5. DOI: 10.1371/Annotation/E0196Ebb-De40-453F-8F8C-791B126618Da  0.337
2009 Ertugrul A, Saka E, Ozdemir H, Vural A, Ozdemir Y, Meltzer HY, Dalkara T. P.3.d.017 Behavioural and molecular effects of N-desmethylclozapine and clozapine in an animal model of schizophrenia European Neuropsychopharmacology. 19. DOI: 10.1016/S0924-977X(09)70899-5  0.335
2009 De Luca V, De Souza R, Viggiano E, Volavka J, Lieberman J, Potkin S, Meltzer H, Wong A, Kennedy J. Genomics, Transcriptomics and Methylomics: Alternative Approaches for the Analysis of Serotonin System and Antipsychotic Response European Psychiatry. 24: 1-1. DOI: 10.1016/S0924-9338(09)71236-2  0.375
2008 Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacological Reviews. 60: 358-403. PMID 18922967 DOI: 10.1124/Pr.107.00107  0.383
2008 Zai CC, Romano-Silva MA, Hwang R, Zai GC, Deluca V, Müller DJ, King N, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL. Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Schizophrenia Research. 106: 248-52. PMID 18838251 DOI: 10.1016/J.Schres.2008.08.036  0.323
2008 Meltzer HY, Brennan MD, Woodward ND, Jayathilake K. Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research. 106: 258-64. PMID 18823757 DOI: 10.1016/J.Schres.2008.08.029  0.388
2008 Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Progress in Brain Research. 172: 177-97. PMID 18772033 DOI: 10.1016/S0079-6123(08)00909-6  0.378
2008 Li Z, Snigdha S, Roseman AS, Dai J, Meltzer HY. Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. European Journal of Pharmacology. 596: 89-97. PMID 18771666 DOI: 10.1016/J.Ejphar.2008.08.009  0.721
2008 Meltzer HY, Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behavioural Brain Research. 195: 98-102. PMID 18707769 DOI: 10.1016/J.Bbr.2008.05.016  0.374
2008 Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, Adams DH, Lindenmayer JP, McEvoy JP, Buckley PF, Lieberman JA, Meltzer HY, Wilson DR, Citrome L. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. Journal of Clinical Psychopharmacology. 28: 392-400. PMID 18626265 DOI: 10.1097/Jcp.0B013E31817E63A5  0.322
2008 Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, Wong AH, Kennedy JL. Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology. 200: 177-86. PMID 18500637 DOI: 10.1007/S00213-008-1193-9  0.375
2008 Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. The Journal of Clinical Psychiatry. 69: 817-29. PMID 18466043 DOI: 10.4088/Jcp.V69N0515  0.349
2008 Huang M, Li Z, Dai J, Shahid M, Wong EH, Meltzer HY. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 2934-45. PMID 18418367 DOI: 10.1038/Npp.2008.20  0.401
2008 Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil YaÄŸcioÄŸlu AE, Small JG. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. The Journal of Clinical Psychiatry. 69: 274-85. PMID 18232726 DOI: 10.4088/Jcp.V69N0214  0.393
2008 Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 1217-28. PMID 17625502 DOI: 10.1038/Sj.Npp.1301499  0.375
2008 Reznik M, Volchek L, Reznik I, Meltzer H, Weizman A. Longitudinal Prospective Evaluation Of Serum Creatine Kinase Levels And Neuromuscular Dysfunction In Schizophrenia Patients: New Results Of Follow-Up Study Schizophrenia Research. 102: 240. DOI: 10.1016/S0920-9964(08)70724-2  0.349
2008 Pedra Souza R, Romano-Silva MA, Lieberman JA, Meltzer HY, Culotti JG, Kennedy JL, Wong AH. GENETIC ASSOCIATION ANALYSIS OF THE GFR ALPHA GENES WITH SCHIZOPHRENIA AND CLOZAPINE RESPONSE Schizophrenia Research. 102: 190. DOI: 10.1016/S0920-9964(08)70577-2  0.321
2008 Tumuklu MN, Kessler RM, Jayathilake K, Meltzer HY. THE RELATIONSHIP BETWEEN DOPAMINE D2 RECEPTOR OCCUPANCY BY ATYPICAL ANTIPSYCHOTIC DRUGS AND COGNITIVE FUNCTION IN PATIENTS WITH SCHIZOPHRENIA Schizophrenia Research. 102: 96. DOI: 10.1016/S0920-9964(08)70289-5  0.394
2008 Kennedy JL, Mueller D, Zai C, Desouza R, Tiwari A, Meltzer H, Lieberman J. PHARMACOGENETICS OF SCHIZOPHRENIA: TARDIVE DYSKINESIA AND WEIGHT GAIN Schizophrenia Research. 102: 34. DOI: 10.1016/S0920-9964(08)70107-5  0.331
2008 Czesak M, Lu J, Stockmeier C, Austin M, Meltzer H, Albert⁎ P. DNA methylation at 5-HT1A receptor promoter C(−1019)G polymorphism CpG sites in schizophrenia and depression Journal of Affective Disorders. 107: S74. DOI: 10.1016/J.Jad.2007.12.049  0.32
2008 Bonaccorso S, Bobo W, Chen Y, Jayathilake K, Meltzer H. Prediction of response in 160 patients with schizophrenia, schizoaffective and bipolar disorder after olanzapine or risperidone treatment European Psychiatry. 23: S155-S156. DOI: 10.1016/J.Eurpsy.2008.01.921  0.359
2008 Sumiyoshi T, Uehara T, Matsuoka T, Higuchi Y, Ito T, Meltzer H. Serotonin-1A agonists as a cognitive enhancer in schizophrenia: Clinical evidence European Psychiatry. 23: S62. DOI: 10.1016/J.Eurpsy.2008.01.226  0.349
2008 Bobo WV, Rapoport JL, Abi-Dargham A, Fatemi H, Meltzer HY, Kandel ER, Polan HJ. The Neurobiology of Schizophrenia Psychiatry: Third Edition. 1: 301-316. DOI: 10.1002/9780470515167.Ch19  0.354
2007 Renou J, De Luca V, Zai CC, Bulgin N, Remington G, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL. Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia. Molecular Psychiatry. 12: 1058-60. PMID 18043709 DOI: 10.1038/Sj.Mp.4002092  0.372
2007 Prus AJ, Huang M, Li Z, Dai J, Meltzer HY. The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: potentiation of risperidone-, but not haloperidol-, induced dopamine efflux. Brain Research. 1184: 354-64. PMID 17988654 DOI: 10.1016/J.Brainres.2007.09.092  0.36
2007 Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. International Clinical Psychopharmacology. 22: 249-67. PMID 17690594 DOI: 10.1097/Yic.0B013E3280De2C7F  0.314
2007 Li Z, Bonhaus DW, Huang M, Prus AJ, Dai J, Meltzer HY. AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. European Journal of Pharmacology. 572: 129-37. PMID 17628522 DOI: 10.1016/J.Ejphar.2007.06.025  0.36
2007 Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophrenia Research. 95: 158-68. PMID 17628435 DOI: 10.1016/j.schres.2007.06.008  0.393
2007 Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry. 64: 633-47. PMID 17548746 DOI: 10.1001/Archpsyc.64.6.633  0.357
2007 Pompili M, Amador XF, Girardi P, Harkavy-Friedman J, Harrow M, Kaplan K, Krausz M, Lester D, Meltzer HY, Modestin J, Montross LP, Mortensen PB, Munk-Jørgensen P, Nielsen J, Nordentoft M, et al. Suicide risk in schizophrenia: learning from the past to change the future. Annals of General Psychiatry. 6: 10. PMID 17367524 DOI: 10.1186/1744-859X-6-10  0.33
2007 Meltzer HY. Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden. Proceedings of the National Academy of Sciences of the United States of America. 104: 3019-20. PMID 17360600 DOI: 10.1073/Pnas.0700090104  0.336
2007 Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. The Journal of Clinical Psychiatry. 68: 213-23. PMID 17335319 DOI: 10.4088/Jcp.V68N0206  0.366
2007 Li Z, Huang M, Prus AJ, Dai J, Meltzer HY. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Research. 1134: 70-8. PMID 17207474 DOI: 10.1016/J.Brainres.2006.11.060  0.402
2007 Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophrenia Research. 90: 86-96. PMID 17123785 DOI: 10.1016/J.Schres.2006.10.002  0.349
2007 Altamura AC, Mundo E, Bassetti R, Green A, Lindenmayer JP, Alphs L, Meltzer HY. Transcultural differences in suicide attempters: analysis on a high-risk population of patients with schizophrenia or schizoaffective disorder. Schizophrenia Research. 89: 140-6. PMID 17097854 DOI: 10.1016/J.Schres.2006.08.023  0.323
2007 Hwang R, Shinkai T, De Luca V, Ni X, Potkin SG, Lieberman JA, Meltzer HY, Kennedy JL. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. Journal of Psychopharmacology (Oxford, England). 21: 718-27. PMID 17092969 DOI: 10.1177/0269881106072341  0.349
2007 Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophrenia Research. 89: 211-24. PMID 17059880 DOI: 10.1016/J.Schres.2006.08.021  0.308
2007 Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. The Journal of Pharmacology and Experimental Therapeutics. 320: 486-96. PMID 17038512 DOI: 10.1124/Jpet.106.106989  0.37
2007 Zai CC, Hwang RW, De Luca V, Müller DJ, King N, Zai GC, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 10: 639-51. PMID 16959057 DOI: 10.1017/S1461145706007152  0.322
2007 McCreary AC, Glennon JC, Ashby CR, Meltzer HY, Li Z, Reinders JH, Hesselink MB, Long SK, Herremans AH, van Stuivenberg H, Feenstra RW, Kruse CG. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 78-94. PMID 16710314 DOI: 10.1038/Sj.Npp.1301098  0.346
2007 Meltzer H, Hargarter L, Kramer M, Sherr J, Gassmann-Mayer C, Lim P, Bobo W, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo-controlled studies (PAL-SCH-303/304/305) Pharmacopsychiatry. 40. DOI: 10.1055/S-2007-991757  0.339
2006 Akdede BB, Anil YaÄŸcioÄŸlu AE, Alptekin K, Turgut TI, Tümüklü M, Yazici MK, Jayathilake K, Tunca Z, Göğüş A, Meltzer HY. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. The Journal of Clinical Psychiatry. 67: 1912-9. PMID 17194269 DOI: 10.4088/Jcp.V67N1211  0.355
2006 Huang M, Li Z, Ichikawa J, Dai J, Meltzer HY. Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex. Brain Research. 1099: 44-55. PMID 16824491 DOI: 10.1016/J.Brainres.2006.04.081  0.383
2006 Meltzer HY, Bobo WV. Interpreting the efficacy findings in the CATIE study: what clinicians should know. Cns Spectrums. 11: 14-24. PMID 16816796 DOI: 10.1017/S109285290002664X  0.376
2006 Basu A, Meltzer HY. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophrenia Research. 86: 99-109. PMID 16753284 DOI: 10.1016/J.Schres.2006.04.014  0.33
2006 Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 1991-2001. PMID 16738543 DOI: 10.1038/Sj.Npp.1301108  0.348
2006 Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 2033-46. PMID 16641947 DOI: 10.1038/Sj.Npp.1301072  0.355
2006 McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry. 163: 600-10. PMID 16585434 DOI: 10.1176/Appi.Ajp.163.4.600  0.395
2006 Huang M, Ichiwaka J, Li Z, Dai J, Meltzer HY. Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology. 185: 274-81. PMID 16521036 DOI: 10.1007/S00213-005-0206-1  0.366
2006 Shinkai T, Müller DJ, De Luca V, Shaikh S, Matsumoto C, Hwang R, King N, Trakalo J, Potapova N, Zai G, Hori H, Ohmori O, Meltzer HY, Nakamura J, Kennedy JL. Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia. Psychiatry Research. 141: 123-8. PMID 16413612 DOI: 10.1016/J.Psychres.2004.06.023  0.31
2006 Sumiyoshi C, Sumiyoshi T, Roy A, Jayathilake K, Meltzer HY. Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 9: 677-83. PMID 16313705 DOI: 10.1017/S1461145705006310  0.322
2006 Hwang R, Shinkai T, Deluca V, Macciardi F, Potkin S, Meltzer HY, Kennedy JL. Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 16: 248-59. PMID 16278074 DOI: 10.1016/J.Euroneuro.2005.09.004  0.326
2006 Basu A, Meltzer HY, Dukic V. Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach. Statistics in Medicine. 25: 2886-910. PMID 16220519 DOI: 10.1002/Sim.2317  0.344
2006 Kaneda Y, Ohmori T, Meltzer HY. A survey to examine psychiatrists?? attitudes and patterns of antipsychotic prescribing practices for schizophrenia in the USA and Japan International Clinical Psychopharmacology. 21: A25. DOI: 10.1097/00004850-200607000-00077  0.336
2006 Sumiyoshi T, Sumiyoshi C, Roy A, Jayathilake K, Meltzer HY. Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling analysis of category fluency performance in schizophrenia International Clinical Psychopharmacology. 21: A16. DOI: 10.1097/00004850-200607000-00051  0.317
2006 Meltzer HY. Testing Multiple Novel Mechanisms for Treating Schizophrenia in a Single Trial Progress in Neurotherapeutics and Neuropsychopharmacology. 1: 115-120. DOI: 10.1017/S174823210500011X  0.337
2006 Ertugrul A, Anil Yagcioglu A, Woodward N, Jayathilake K, Meltzer H. P.3.c.018 Genetic predictors of cognitive function and response to treatment in schizophrenia European Neuropsychopharmacology. 16: S406. DOI: 10.1016/S0924-977X(06)70505-3  0.33
2006 Meltzer H, Prus A. NK3 receptor antagonists for the treatment of schizophrenia Drug Discovery Today: Therapeutic Strategies. 3: 555-560. DOI: 10.1016/J.Ddstr.2006.11.013  0.408
2006 Meltzer HY, Li Z, Huang M, Prus A. Serotonergic mechanisms in schizophrenia: Evolution and current concepts Current Psychosis and Therapeutics Reports. 4: 12-19. DOI: 10.1007/Bf02629409  0.395
2005 Spooren W, Riemer C, Meltzer H. NK3 receptor antagonists: The next generation of antipsychotics? Nature Reviews Drug Discovery. 4: 967-975. PMID 16341062 DOI: 10.1038/Nrd1905  0.386
2005 Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology. 183: 144-53. PMID 16220333 DOI: 10.1007/S00213-005-0170-9  0.344
2005 Müller DJ, De Luca V, Sicard T, King N, Hwang R, Volavka J, Czobor P, Sheitman BB, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA, Meltzer HY, Kennedy JL. Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 15: 525-31. PMID 16139171 DOI: 10.1016/J.Euroneuro.2005.02.001  0.333
2005 McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research. 80: 19-32. PMID 16137860 DOI: 10.1016/J.Schres.2005.07.014  0.339
2005 Ichikawa J, Chung YC, Dai J, Meltzer HY. Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release. Brain Research. 1052: 56-62. PMID 16061211 DOI: 10.1016/J.Brainres.2005.06.009  0.39
2005 Shinkai T, De Luca V, Hwang R, Matsumoto C, Hori H, Ohmori O, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Nakamura J, Kennedy JL. Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia. Neuroscience Letters. 388: 116-20. PMID 16039055 DOI: 10.1016/J.Neulet.2005.06.038  0.308
2005 Ichikawa J, Dai J, Meltzer HY. Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: role of 5-HT(1A) receptor agonism. Brain Research. 1049: 182-90. PMID 15936730 DOI: 10.1016/J.Brainres.2005.05.005  0.328
2005 Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 30: 1986-95. PMID 15900318 DOI: 10.1038/Sj.Npp.1300768  0.358
2005 Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN, Strous R, Chong SA, Heresco-Levy U, Verga M, Scharfetter J, Meltzer HY, Kennedy JL, Macciardi F. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 8: 411-25. PMID 15857569 DOI: 10.1017/S1461145705005389  0.326
2005 Hwang R, Shinkai T, De Luca V, Müller DJ, Ni X, Macciardi F, Potkin S, Lieberman JA, Meltzer HY, Kennedy JL. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology. 181: 179-87. PMID 15830237 DOI: 10.1007/S00213-005-2223-5  0.355
2005 Sumiyoshi T, Jin D, Jayathilake K, Lee M, Meltzer HY. Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 8: 451-5. PMID 15817136 DOI: 10.1017/S1461145705005237  0.392
2005 Meltzer HY. Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine. The Journal of Clinical Psychiatry. 66: 530-3. PMID 15816797 DOI: 10.4088/Jcp.V66N0417  0.343
2005 Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 8: 457-72. PMID 15784157 DOI: 10.1017/S146114570500516X  0.31
2005 Meltzer HY. Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences? The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 8: 153-6. PMID 15780147 DOI: 10.1017/S1461145705005183  0.341
2005 Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology. 178: 451-60. PMID 15765260 DOI: 10.1007/S00213-004-2017-1  0.302
2005 Green MF, Barnes TR, Danion JM, Gallhofer B, Meltzer HY, Pantelis C. The FOCIS international survey on psychiatrists' opinions on cognition in schizophrenia. Schizophrenia Research. 74: 253-61. PMID 15722004 DOI: 10.1016/J.Schres.2004.05.023  0.367
2005 Anil YaÄŸcioÄŸlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, ErtuÄŸrul A, Jayathilake K, Göğüş A, Tunca Z, Meltzer HY. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. The Journal of Clinical Psychiatry. 66: 63-72. PMID 15669890 DOI: 10.4088/Jcp.V66N0109  0.374
2004 Meltzer HY. Cognitive factors in schizophrenia: causes, impact, and treatment. Cns Spectrums. 9: 15-24. PMID 15475873 DOI: 10.1017/S1092852900025098  0.313
2004 Ertugrul A, Kennedy JL, Masellis M, Basile VS, Jayathilake K, Meltzer HY. No association of the T102C polymorphism of the serotonin 2A receptor gene (HTR2A) with suicidality in schizophrenia. Schizophrenia Research. 69: 301-5. PMID 15469201 DOI: 10.1016/S0920-9964(03)00126-9  0.351
2004 Chung YC, Li Z, Dai J, Meltzer HY, Ichikawa J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Research. 1023: 54-63. PMID 15364019 DOI: 10.1016/J.Brainres.2004.07.009  0.35
2004 Bourgeois M, Swendsen J, Young F, Amador X, Pini S, Cassano GB, Lindenmayer JP, Hsu C, Alphs L, Meltzer HY. Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial. The American Journal of Psychiatry. 161: 1494-6. PMID 15285981 DOI: 10.1176/Appi.Ajp.161.8.1494  0.307
2004 Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology. 177: 207-16. PMID 15258717 DOI: 10.1007/S00213-004-1940-5  0.367
2004 Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. European Journal of Pharmacology. 493: 75-83. PMID 15189766 DOI: 10.1016/J.Ejphar.2004.04.028  0.341
2004 Sumiyoshi T, Roy A, Kim CH, Jayathilake K, Lee MA, Sumiyoshi C, Meltzer HY. Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia. Psychopharmacology. 177: 79-83. PMID 15179543 DOI: 10.1007/S00213-004-1924-5  0.362
2004 Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. The American Journal of Psychiatry. 161: 975-84. PMID 15169685 DOI: 10.1176/Appi.Ajp.161.6.975  0.367
2004 Jaskiw GE, Hussain G, Stephans SE, Yamamoto BK, Meltzer HY. Clozapine prolongs hypotonic immobility in rats with bilateral 6-hydroxydopamine lesions of the striatum. Neuroscience Letters. 362: 35-8. PMID 15147775 DOI: 10.1016/J.Neulet.2004.01.079  0.321
2004 Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, Romano SJ. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophrenia Research. 66: 101-13. PMID 15061242 DOI: 10.1016/J.Schres.2003.07.009  0.34
2004 Meltzer HY. What's atypical about atypical antipsychotic drugs? Current Opinion in Pharmacology. 4: 53-7. PMID 15018839 DOI: 10.1016/J.Coph.2003.09.010  0.348
2004 Prus AJ, Baker LE, Meltzer HY. Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms. Pharmacology, Biochemistry, and Behavior. 77: 199-208. PMID 14751446 DOI: 10.1016/J.Pbb.2003.10.010  0.605
2004 Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 7: 1-8. PMID 14720317 DOI: 10.1017/S1461145703003900  0.399
2004 Sumiyoshi T, Meltzer HY, Jayathilake K. Melperone, an atypical antipsychotic drug, in the treatment of schizophrenia: dose-response analysis on effectiveness and tolerability, and efficacy for treatment-resistant schizophrenia and cognitive function International Clinical Psychopharmacology. 19: 184. DOI: 10.1097/00004850-200405000-00039  0.379
2003 Meltzer HY. Beyond control of acute exacerbation: enhancing affective and cognitive outcomes. Cns Spectrums. 8: 16-8, 22. PMID 14978453 DOI: 10.1017/S1092852900008142  0.303
2003 Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 1159-72. PMID 14642974 DOI: 10.1016/J.Pnpbp.2003.09.010  0.378
2003 Meltzer HY, Baldessarini RJ. Reducing the risk for suicide in schizophrenia and affective disorders. The Journal of Clinical Psychiatry. 64: 1122-9. PMID 14628990 DOI: 10.4088/Jcp.V64N0920  0.328
2003 Ertugrul A, Meltzer HY. Antipsychotic drugs in bipolar disorder. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 6: 277-84. PMID 12974994 DOI: 10.1017/S1461145703003560  0.361
2003 Keefe RS, Mohs RC, Bilder RM, Harvey PD, Green MF, Meltzer HY, Gold JM, Sano M. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophrenia Bulletin. 29: 45-55. PMID 12908660 DOI: 10.1093/Oxfordjournals.Schbul.A006990  0.349
2003 Li Z, Kim CH, Ichikawa J, Meltzer HY. Effect of repeated administration of phencyclidine on spatial performance in an eight-arm radial maze with delay in rats and mice. Pharmacology, Biochemistry, and Behavior. 75: 335-40. PMID 12873624 DOI: 10.1016/S0091-3057(03)00085-6  0.32
2003 Sumiyoshi T, Jayathilake K, Meltzer HY. A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia. Schizophrenia Research. 62: 65-72. PMID 12765745 DOI: 10.1016/S0920-9964(02)00351-1  0.386
2003 Kuroki T, Meltzer HY, Ichikawa J. 5-HT 2A receptor stimulation by DOI, a 5-HT 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Research. 972: 216-21. PMID 12711095 DOI: 10.1016/S0006-8993(03)02516-2  0.334
2003 Li Z, Ichikawa J, Meltzer HY. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Psychopharmacology. 167: 315-23. PMID 12664192 DOI: 10.1007/S00213-003-1418-X  0.369
2003 Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 519-26. PMID 12629531 DOI: 10.1038/Sj.Npp.1300027  0.343
2003 Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology. 169: 404-11. PMID 12590356 DOI: 10.1007/S00213-002-1342-5  0.324
2003 Meltzer HY, Sumiyoshi T. Atypical antipsychotic drugs improve cognition in schizophrenia. Biological Psychiatry. 53: 265-7; author reply . PMID 12559661 DOI: 10.1016/S0006-3223(02)01790-0  0.356
2003 Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry. 60: 82-91. PMID 12511175 DOI: 10.1001/Archpsyc.60.1.82  0.303
2003 Kim CH, Jayathilake K, Meltzer HY. Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior. Schizophrenia Research. 60: 71-80. PMID 12505140 DOI: 10.1016/S0920-9964(02)00310-9  0.341
2003 Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophrenia Research. 59: 19-27. PMID 12413638 DOI: 10.1016/S0920-9964(01)00326-7  0.311
2003 Sumiyoshi T, Jayathilake K, Meltzer HY. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia. Schizophrenia Research. 59: 7-16. PMID 12413636 DOI: 10.1016/S0920-9964(01)00329-2  0.378
2003 McQuade R, Jody D, Kane J, Carson W, Kujawa M, Stringfellow J, Marcus R, Sanchez R, Meltzer H. P.2.105 Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia European Neuropsychopharmacology. 13: S326. DOI: 10.1016/S0924-977X(03)92058-X  0.321
2003 Kessler R, Ansari M, Lui R, Dawant B, Meltzer H. Occupancy of cortical and substantia nigra DA D2 receptors by typical and atypical antipsychotic drugs Schizophrenia Research. 60: 242-243. DOI: 10.1016/S0920-9964(03)81249-5  0.321
2003 Sumiyoshi T, Park S, Ertugrul A, Clemmons F, Jayathilake K, Meltzer H. The effect of buspirone, a serotonin1A agonist, on cognitive function in schizophrenia Schizophrenia Research. 60: 304. DOI: 10.1016/S0920-9964(03)80230-X  0.352
2003 Reznik I, Mester R, Spivak B, Kotler M, Weizman A, Meltzer H. The incidence of the serum creatine kinase elevation in schizophrenia and schizoaffective patients during antipsychotic treatment Schizophrenia Research. 60: 366. DOI: 10.1016/S0920-9964(03)80196-2  0.365
2003 Meltzer HY. Erratum: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) (Archives of General Psychiatry (January 2003) 60 (82-91)) Archives of General Psychiatry. 60. DOI: 10.1001/Archpsyc.60.7.735  0.334
2002 Tsai SJ, Hong CJ, Yu YWY, Lin CH, Basile VS, Masellis M, De Luca V, Meltzer HY, Kennedy JL. -759C/T genetic variation of 5HT2C receptor and clozapine-induced weight gain [8] (multiple letters) Lancet. 360: 1790-1791. PMID 12480466 DOI: 10.1016/S0140-6736(02)11705-3  0.326
2002 Ichikawa J, Chung YC, Li Z, Dai J, Meltzer HY. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Research. 958: 176-84. PMID 12468043 DOI: 10.1016/S0006-8993(02)03692-2  0.312
2002 Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Research. 956: 349-57. PMID 12445705 DOI: 10.1016/S0006-8993(02)03570-9  0.327
2002 Bonaccorso S, Meltzer HY, Li Z, Dai J, Alboszta AR, Ichikawa J. SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 27: 430-41. PMID 12225700 DOI: 10.1016/S0893-133X(02)00311-1  0.337
2002 Meltzer HY. Commentary on "clinical studies on the mechanism of action of clozapine; the dopamine-serotonin hypothesis of schizophrenia." Psychopharmacology (1989) 99:S18-S27. Psychopharmacology. 163: 1-3. PMID 12185394 DOI: 10.1007/S00213-002-1088-0  0.368
2002 Arato M, O'Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. International Clinical Psychopharmacology. 17: 207-15. PMID 12177583 DOI: 10.1097/00004850-200209000-00001  0.327
2002 Liégeois JF, Ichikawa J, Meltzer HY. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Research. 947: 157-65. PMID 12176156 DOI: 10.1016/S0006-8993(02)02620-3  0.328
2002 Stockmeier CA, Shi X, Konick L, Overholser JC, Jurjus G, Meltzer HY, Friedman L, Blier P, Rajkowska G. Neurokinin-1 receptors are decreased in major depressive disorder. Neuroreport. 13: 1223-7. PMID 12151774 DOI: 10.1097/00001756-200207020-00031  0.303
2002 Meltzer HY. Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Current Psychiatry Reports. 4: 279-83. PMID 12126596 DOI: 10.1007/S11920-996-0047-6  0.346
2002 Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, McCreadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, ... ... Meltzer HY, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 27: 105-19. PMID 12062911 DOI: 10.1016/S0893-133X(02)00293-2  0.312
2002 Ichikawa J, Dai J, Meltzer HY. 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Research. 939: 34-42. PMID 12020849 DOI: 10.1016/S0006-8993(02)02544-1  0.314
2002 Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 26: 325-39. PMID 11850147 DOI: 10.1016/S0893-133X(01)00312-8  0.357
2002 Meltzer HY. Action of atypical antipsychotics. The American Journal of Psychiatry. 159: 153-4; author reply . PMID 11772718 DOI: 10.1176/Appi.Ajp.159.1.153-A  0.329
2002 Meltzer H, Kessler R, Li Z, Chung Y, Ichikawa J. Effects on serotonin and dopamine receptors in the mechanism of atypical antipsychotic drugs European Neuropsychopharmacology. 12: 164-165. DOI: 10.1016/S0924-977X(02)80117-1  0.356
2002 Meltzer H. Ziprasidone's long-term efficacy and tolerability in schizophrenia European Psychiatry. 17: 101. DOI: 10.1016/S0924-9338(02)80458-8  0.319
2002 Meltzer H. Neuromuscular abnormalities in psychosis; implications for nosology, neurodevelopment and neurotransmitter abnormalities European Psychiatry. 17: 44. DOI: 10.1016/S0924-9338(02)80197-3  0.303
2002 Bonaccorso S, Meltzer HY, Li Z, Dai J, Alboszta AR, Ichikawa J. Erratum: SR46349-B, a 5-HT2A/2C receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens (Neuropsychopharmacology (September 2002) 27:3 (430-441) PII:S0893133X02003111) Neuropsychopharmacology. 27. DOI: 10.1016/S0893-133X(02)00440-2  0.362
2001 Meltzer HY, Sumiyoshi T, Jayathilake K. Melperone in the treatment of neuroleptic-resistant schizophrenia. Psychiatry Research. 105: 201-9. PMID 11814539 DOI: 10.1016/S0165-1781(01)00346-8  0.388
2001 Lee MA, Meltzer HY. 5-HT(1A) receptor dysfunction in female patients with schizophrenia. Biological Psychiatry. 50: 758-66. PMID 11720694 DOI: 10.1016/S0006-3223(01)01202-1  0.362
2001 Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, Jayathilake K, Meltzer HY. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. The American Journal of Psychiatry. 158: 1722-5. PMID 11579010 DOI: 10.1176/Appi.Ajp.158.10.1722  0.396
2001 Ichikawa J, Dai J, Meltzer HY. DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Research. 907: 151-5. PMID 11430898 DOI: 10.1016/S0006-8993(01)02596-3  0.34
2001 Meltzer HY. Treatment of suicidality in schizophrenia. Annals of the New York Academy of Sciences. 932: 44-58; discussion 58. PMID 11411190 DOI: 10.1111/J.1749-6632.2001.Tb05797.X  0.351
2001 Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, Sumiyoshi S, Sumiyoshi C, Meltzer HY. The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biological Psychiatry. 49: 861-8. PMID 11343682 DOI: 10.1016/S0006-3223(00)01025-8  0.353
2001 Basile VS, Ozdemir V, Masellis M, Meltzer HY, Lieberman JA, Potkin SG, Macciardi FM, Petronis A, Kennedy JL. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Molecular Psychiatry. 6: 230-4. PMID 11317228 DOI: 10.1038/Sj.Mp.4000847  0.373
2001 Niswender CM, Herrick-Davis K, Dilley GE, Meltzer HY, Overholser JC, Stockmeier CA, Emeson RB, Sanders-Bush E. RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 24: 478-91. PMID 11282248 DOI: 10.1016/S0893-133X(00)00223-2  0.316
2001 Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry. 76: 1521-31. PMID 11238736 DOI: 10.1046/J.1471-4159.2001.00154.X  0.338
2001 Meltzer HY, Lee MA, Jayathilake K. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 24: 278-90. PMID 11166518 DOI: 10.1016/S0893-133X(00)00201-3  0.366
2001 Masellis M, Basile VS, Meltzer HY, Lieberman JA, Sevy S, Goldman DA, Hamblin MW, Macciardi FM, Kennedy JL. Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophrenia Research. 47: 49-58. PMID 11163544 DOI: 10.1016/S0920-9964(00)00016-5  0.348
2001 Gallhofer B, Green MP, Barnes T, Danion J-, Meltzer HY, Pantelis C. FOCIS: An international survey on cognitive dysfunction in schizophrenia European Neuropsychopharmacology. 11. DOI: 10.1016/S0924-977X(01)80344-8  0.33
2001 Meltzer H. Long-term efficacy of ziprasidone in schizophrenia European Neuropsychopharmacology. 11: S273. DOI: 10.1016/S0924-977X(01)80340-0  0.324
2001 Harvey P, Mahmoud R, Meltzer H, Green M. Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder European Neuropsychopharmacology. 11: S257. DOI: 10.1016/S0924-977X(01)80302-3  0.359
2000 McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophrenia Research. 45: 175-84. PMID 11042435 DOI: 10.1016/S0920-9964(99)00198-X  0.337
2000 Al-Semaan YM, Clay HA, Meltzer HY. Clozapine in treatment of bromocriptine-induced psychosis. Journal of Clinical Psychopharmacology. 17: 126-8. PMID 10950481 DOI: 10.1097/00004714-199704000-00016  0.304
2000 Kuroki T, Dai J, Meltzer HY, Ichikawa J. R(+)-8-OH-DPAT, a selective 5-HT(1A) receptor agonist, attenuated amphetamine-induced dopamine synthesis in rat striatum, but not nucleus accumbens or medial prefrontal cortex. Brain Research. 872: 204-7. PMID 10924694 DOI: 10.1016/S0006-8993(00)02437-9  0.313
2000 Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, Potkin SG, Alva G, Kalow W, Macciardi FM, Kennedy JL. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Molecular Psychiatry. 5: 410-7. PMID 10889552 DOI: 10.1038/Sj.Mp.4000736  0.341
2000 Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M, Meltzer HY. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. Journal of Clinical Psychopharmacology. 20: 386-8. PMID 10831031 DOI: 10.1097/00004714-200006000-00019  0.348
2000 Buckley PF, Friedman L, Wu D, Lai S, Meltzer HY, Haacke EM, Miller D, Lewin JS. Functional magnetic resonance imaging in schizophrenia: initial methodology and evaluation of the motor cortex. Psychiatry Research. 74: 13-23. PMID 10710159 DOI: 10.1016/S0925-4927(96)02931-9  0.311
2000 Ichikawa J, Meltzer HY. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Research. 858: 252-63. PMID 10708676 DOI: 10.1016/S0006-8993(99)02346-X  0.349
2000 Masellis M, Basile VS, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL. Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine. Biological Psychiatry. 47: 252-66. PMID 10682223 DOI: 10.1016/S0006-3223(99)00298-X  0.363
2000 Meltzer HY. Genetics and etiology of schizophrenia and bipolar disorder. Biological Psychiatry. 47: 171-3. PMID 10682214 DOI: 10.1016/S0006-3223(99)00303-0  0.327
2000 Meltzer HY, Anand R, Alphs L. Reducing Suicide Risk in Schizophrenia Cns Drugs. 14: 355-365. DOI: 10.2165/00023210-200014050-00003  0.353
2000 Meltzer H, Arato M, O'Connor R. Path analysis of the Zeus study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable, schizophrenia Schizophrenia Research. 41: 208-209. DOI: 10.1016/S0920-9964(00)90817-X  0.343
1999 Ichikawa J, Meltzer HY. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. European Archives of Psychiatry and Clinical Neuroscience. 249: 90-8. PMID 10654114 DOI: 10.1007/Pl00014190  0.364
1999 Meltzer HY. Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biological Psychiatry. 46: 1321-7. PMID 10578448 DOI: 10.1016/S0006-3223(99)00255-3  0.335
1999 Meltzer HY, Park S, Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proceedings of the National Academy of Sciences of the United States of America. 96: 13591-3. PMID 10570115 DOI: 10.1073/Pnas.96.24.13591  0.369
1999 Ichikawa J, Meltzer HY. The effect of ipsapirone and S(-)-pindolol on dopamine release in rat striatum and nucleus accumbens. Brain Research. 842: 445-51. PMID 10526141 DOI: 10.1016/S0006-8993(99)01876-4  0.344
1999 Ichikawa J, Meltzer HY. Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation. European Journal of Pharmacology. 380: R1-3. PMID 10513560 DOI: 10.1016/S0014-2999(99)00517-8  0.34
1999 Young CD, Bubser M, Meltzer HY, Deutch AY. Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation. Psychopharmacology. 144: 255-63. PMID 10435392 DOI: 10.1007/S002130051001  0.361
1999 Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 21: 106S-115S. PMID 10432496 DOI: 10.1016/S0893-133X(99)00046-9  0.388
1999 Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin. 25: 233-55. PMID 10416729 DOI: 10.1093/Oxfordjournals.Schbul.A033376  0.337
1999 Meltzer HY. Risperidone and clozapine for treatment-resistant schizophrenia. The American Journal of Psychiatry. 156: 1126-7; author reply. PMID 10401484 DOI: 10.1176/Ajp.156.7.1126  0.348
1999 Vincent JB, Petronis A, Strong E, Parikh SV, Meltzer HY, Lieberman J, Kennedy JL. Analysis of genome-wide CAG/CTG repeats, and at SEF2-1B and ERDA1 in schizophrenia and bipolar affective disorder. Molecular Psychiatry. 4: 229-34. PMID 10395212 DOI: 10.1038/Sj.Mp.4000498  0.316
1999 Klimek V, Rajkowska G, Luker SN, Dilley G, Meltzer HY, Overholser JC, Stockmeier CA, Ordway GA. Brain noradrenergic receptors in major depression and schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 21: 69-81. PMID 10379521 DOI: 10.1016/0006-3223(96)84243-0  0.305
1999 Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA, Potkin SG, Macciardi F, Kennedy JL. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 21: 17-27. PMID 10379516 DOI: 10.1016/S0893-133X(98)00114-6  0.367
1999 Lee MA, Jayathilake K, Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia Schizophrenia Research. 37: 1-11. PMID 10227103 DOI: 10.1016/S0920-9964(98)00145-5  0.37
1999 Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. Journal of Clinical Psychopharmacology. 19: 177-82. PMID 10211920 DOI: 10.1097/00004714-199904000-00014  0.345
1999 Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Rivière ME, Papillon-Downey C. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. The American Journal of Psychiatry. 156: 419-25. PMID 10080558 DOI: 10.1176/Ajp.156.3.419  0.382
1999 Özdemir V, Masellis M, Basile VS, Kalow W, Meltzer HY, Lieberman JA, Kennedy JL. Variability in Response to Clozapine: Potential Role of Cytochrome P450 1A2 and the Dopamine D4 Receptor Gene Cns Spectrums. 4: 30-34, 47-56. DOI: 10.1017/S109285290001186X  0.408
1998 Ichikawa J, Kuroki T, Meltzer HY. Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in rat nucleus accumbens. European Journal of Pharmacology. 350: 159-64. PMID 9696403 DOI: 10.1016/S0014-2999(98)00247-7  0.363
1998 Hong WW, Rak IW, Ciuryla VT, Wilson AM, Kylstra JW, Meltzer HY, Carpenter WT, Lehman A, Arvanitis LA. Medical-claims databases in the design of a health-outcomes comparison of quetiapine ('Seroquel') and usual-care antipsychotic medication. Schizophrenia Research. 32: 51-8. PMID 9690334 DOI: 10.1016/S0920-9964(98)00040-1  0.35
1998 Ichikawa J, Kuroki T, Dai J, Meltzer HY. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. European Journal of Pharmacology. 351: 163-71. PMID 9686999 DOI: 10.1016/S0014-2999(98)00308-2  0.376
1998 Meltzer HY, Lee M, Cola P. The evolution of treatment resistance: biologic implications. Journal of Clinical Psychopharmacology. 18: 5S-11S. PMID 9555610 DOI: 10.1097/00004714-199804001-00003  0.347
1998 Meltzer HY. Treatment-resistant schizophrenia--the role of clozapine. Current Medical Research and Opinion. 14: 1-20. PMID 9524789 DOI: 10.1185/03007999709113338  0.381
1998 Willins DL, Meltzer HY. Serotonin 5-HT2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens. Brain Research. 781: 291-9. PMID 9507167 DOI: 10.1016/S0006-8993(97)01267-5  0.316
1998 Roth BL, Meltzer HY, Khan N. Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. Advances in Pharmacology (San Diego, Calif.). 42: 482-5. PMID 9327944 DOI: 10.1016/S1054-3589(08)60793-0  0.371
1998 Arato M, O’Connor R, Bradbury J, Meltzer H. Ziprasidone in the long-term treatment of negative symptoms and prevention of exacerbation of schizophrenia European Psychiatry. 13: 303s-303s. DOI: 10.1016/S0924-9338(99)80610-5  0.335
1998 Summerfelt WT, Jayathilake K, Meltzer H. Relationship between quality of life and symptomatology in schizophrenia Schizophrenia Research. 29: 189. DOI: 10.1016/S0920-9964(97)88788-9  0.304
1998 Petronis A, Vincent J, Paterson A, Bassett A, Honer W, Gottesman I, Fuller Torrey E, Meltzer H, Lieberman J, Kennedy J. Search for unstable DNA in schizophrenia Schizophrenia Research. 29: 135. DOI: 10.1016/S0920-9964(97)88642-2  0.315
1997 Bruhwyler J, Liégeois JF, Bergman J, Carey G, Goudie A, Taylor A, Meltzer H, Delarge J, Géczy J. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioural properties Pharmacological Research. 36: 255-264. PMID 9425613 DOI: 10.1006/Phrs.1997.0231  0.329
1997 Maes M, Westenberg H, Vandoolaeghe E, Demedts P, Wauters A, Neels H, Meltzer HY. Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. Journal of Clinical Psychopharmacology. 17: 358-64. PMID 9315986 DOI: 10.1097/00004714-199710000-00004  0.307
1997 Meltzer HY, Baldessarini RJ, Tarazi FI, Kula NS, Gardner DM, Seeman P. Clozapine withdrawal: Serotonergic or dopaminergic mechanisms? [1] (multiple letters) Archives of General Psychiatry. 54: 760-763. PMID 9283512 DOI: 10.1001/Archpsyc.1997.01830200094013  0.357
1997 Maes M, Calabrese J, Jayathilake K, Meltzer HY. Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Research. 71: 67-76. PMID 9255851 DOI: 10.1016/S0165-1781(97)00046-2  0.301
1997 Meltzer H, Bastani B, Jayathilake K, Maes M. Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder Neuropsychopharmacology. 17: 1-11. PMID 9194044 DOI: 10.1016/S0893-133X(96)00280-1  0.338
1997 Sumiyoshi T, Ichikawa J, Meltzer HY. The effect of streptozotocin-induced diabetes on dopamine2, serotonin1A and serotonin2A receptors in the rat brain. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 16: 183-90. PMID 9138434 DOI: 10.1016/S0893-133X(96)00185-6  0.309
1997 Sumiyoshi T, Hasegawa M, Jayathilake K, Meltzer HY. Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiatry Research. 69: 113-21. PMID 9109179 DOI: 10.1016/S0165-1781(96)02993-9  0.349
1997 Herz MI, Liberman RP, McGlashan TH, Lieberman JA, Wyatt RJ, Marder SR, Wang P, Allgulander C, Baldessarini RJ, Balon R, Bellack AS, Berlin CMJ, Blackington CH, Buckley P, Carlson DG, ... ... Meltzer HY, et al. Practice guideline for the treatment of patients with schizophrenia American Journal of Psychiatry. 154: 1-63. PMID 9090368 DOI: 10.1176/Ajp.154.4.1  0.351
1997 Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, Thompson PA. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. The American Journal of Psychiatry. 154: 475-82. PMID 9090333 DOI: 10.1176/Ajp.154.4.475  0.304
1997 Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, Scharpé S. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Research. 66: 1-11. PMID 9061799 DOI: 10.1016/S0165-1781(96)02915-0  0.333
1997 Sumiyoshi T, Hasegawa M, Jayathilake K, Meltzer HY. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance. Biological Psychiatry. 41: 560-6. PMID 9046988 DOI: 10.1016/S0006-3223(96)00099-6  0.335
1997 Kuroki T, Ichikawa J, Dai J, Meltzer HY. R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Brain Research. 743: 357-61. PMID 9017269 DOI: 10.1016/S0006-8993(96)01111-0  0.339
1997 Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, Meltzer HY. Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 16: 162-73. PMID 9015799 DOI: 10.1016/S0893-133X(96)00170-4  0.311
1997 Maes M, Meltzer HY. Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers. Psychiatry Research. 64: 147-59. PMID 8944393 DOI: 10.1016/S0165-1781(96)02917-4  0.396
1997 Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 15: 395-405. PMID 8887994 DOI: 10.1016/0893-133X(95)00276-J  0.329
1997 Findling RL, Jayathilake K, Meltzer HY. Pre-morbid asociality in neuroleptic-resistant and neuroleptic-responsive schizophrenia. Psychological Medicine. 26: 1033-41. PMID 8878335 DOI: 10.1017/S0033291700035352  0.338
1997 Elkis H, Friedman L, Buckley PF, Lee HS, Lys C, Kaufman B, Meltzer HY. Increased prefrontal sulcal prominence in relatively young patients with unipolar major depression. Psychiatry Research. 67: 123-34. PMID 8876012 DOI: 10.1016/0925-4927(96)02744-8  0.351
1997 Arató M, O'Connor R, Meltzer H, Bradbury J. P.2.067 Ziprasidone: Efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia European Neuropsychopharmacology. 7. DOI: 10.1016/S0924-977X(97)88702-0  0.333
1997 Vincent JB, Meltzer H, Lieberman J, Breschel T, McGinnis M, Macedo A, Azevedo M, Pato C, Torrey E, Gottesman I, Petronis A, Kennedy J. Large or expanded CAG/CTG trinucleotide repeats as an etiological factor in schizophrenia Schizophrenia Research. 24: 55. DOI: 10.1016/S0920-9964(97)82157-3  0.345
1996 Maes M, Bosmans E, Ranjan R, Vandoolaeghe E, Meltzer HY, Ley MD, Berghmans R, Stans G, Desnyder R. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs Schizophrenia Research. 21: 39-50. PMID 8998275 DOI: 10.1016/0920-9964(96)00029-1  0.358
1996 Meltzer HY, Lee MA, Ranjan R, Mason EA, Cola PA. Relapse following clozapine withdrawal: Effect of neuroleptic drugs and cyproheptadine Psychopharmacology. 124: 176-187. PMID 8935814 DOI: 10.1007/Bf02245619  0.378
1996 Maes M, Meester ID, Scharpe S, Desnyder R, Ranjan R, Meltzer HY. Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs Acta Psychiatrica Scandinavica. 93: 1-8. PMID 8919323 DOI: 10.1111/J.1600-0447.1996.Tb10612.X  0.354
1996 Hudson CJ, Kennedy JL, Gotowiec A, Lin A, King N, Gojtan K, Macciardi F, Skorecki K, Meltzer HY, Warsh JJ, Horrobin DF. Genetic variant near cytosolic phospholipase A2 associated with schizophrenia Schizophrenia Research. 21: 111-116. PMID 8873778 DOI: 10.1016/0920-9964(96)00031-X  0.342
1996 Ranjan R, Meltzer HY. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression Biological Psychiatry. 40: 253-258. PMID 8871771 DOI: 10.1016/0006-3223(95)00305-3  0.356
1996 Meltzer HY, Thompson PA, Lee MA, Ranjan R. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 14: 27S-33S. PMID 8866741 DOI: 10.1016/0893-133X(95)00202-O  0.361
1996 Sasaki T, Macciardi FM, Badri F, Verga M, Meltzer HY, Lieberman J, Howard A, Bean G, Joffe RT, Hudson CJ, Kennedy JL. No evidence for association of dopamine D2 receptor variant (Ser311/Cys311) with major psychosis. American Journal of Medical Genetics. 67: 415-7. PMID 8837713 DOI: 10.1002/(Sici)1096-8628(19960726)67:4<415::Aid-Ajmg18>3.0.Co;2-M  0.381
1996 Kennedy JL, Billett EA, Macciardi FM, Verga M, Parsons TJ, Meltzer HY, Lieberman J, Buchanan JA. Association study of dopamine D3 receptor gene and schizophrenia. American Journal of Medical Genetics. 60: 558-62. PMID 8825896 DOI: 10.1002/Ajmg.1320600615  0.382
1996 Maes M, Van Gastel A, Meltzer HY, Cosyns P, Blockx P, Desnyder R. Acute administration of buspirone increases the escape of hypothalamic-pituitary-adrenal-axis hormones from suppression by dexamethasone in depression. Psychoneuroendocrinology. 21: 67-81. PMID 8778905 DOI: 10.1016/0306-4530(95)00028-3  0.303
1996 Sumiyoshi T, Stockmeier CA, Overholser JC, Dilley GE, Meltzer HY. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Research. 708: 209-14. PMID 8720882 DOI: 10.1016/0924-977X(96)88299-X  0.363
1996 Meltzer HY, Maes M. Effects of ipsapirone on plasma cortisol and body temperature in major depression. Biological Psychiatry. 38: 450-7. PMID 8672605 DOI: 10.1016/0006-3223(94)00370-I  0.324
1996 Ichikawa J, Meltzer HY. DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Research. 698: 204-8. PMID 8581482 DOI: 10.1016/0006-8993(95)00865-N  0.317
1996 Maes M, Goossens F, Scharpé S, Calabrese J, Desnyder R, Meltzer HY. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Research. 58: 217-25. PMID 8570777 DOI: 10.1016/0165-1781(95)02698-V  0.364
1996 Meltzer HY, Maes M. Pindolol pretreatment blocks stimulation by meta-chlorophenylpiperazine of prolactin but not cortisol secretion in normal men. Psychiatry Research. 58: 89-98. PMID 8570772 DOI: 10.1016/0165-1781(95)02701-W  0.33
1996 Sasaki T, Billett E, Petronis A, Ying D, Parsons T, Macciardi FM, Meltzer HY, Lieberman J, Joffe RT, Ross CA, McInnis MG, Li SH, Kennedy JL. Psychosis and genes with trinucleotide repeat polymorphism. Human Genetics. 97: 244-6. PMID 8566962 DOI: 10.1007/Bf02265274  0.318
1996 Petronis A, Macciardi F, Athanassiades A, Paterson AD, Verga M, Meltzer HY, Cola P, Buchanan JA, Van Tol HH, Kennedy JL. Association study between the dopamine D4 receptor gene and schizophrenia. American Journal of Medical Genetics. 60: 452-5. PMID 8546161 DOI: 10.1002/Ajmg.1320600518  0.392
1996 Ichikawa J, Meltzer HY. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. European Journal of Pharmacology. 281: 255-61. PMID 8521908 DOI: 10.1016/0014-2999(95)00264-L  0.347
1996 Meltzer HY, Maes M. Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. Biological Psychiatry. 38: 310-8. PMID 7495925 DOI: 10.1016/0006-3223(95)00301-V  0.328
1996 Meltzer HY. Pre-clinical Pharmacology of Atypical Antipsychotic Drugs: A Selective Review British Journal of Psychiatry. 168: 23-31. DOI: 10.1192/S0007125000298280  0.347
1996 Meltzer H, Ichikawa J, Kuroki T, Roth B. Serotonin-related strategies for the treatment of schizophrenia European Neuropsychopharmacology. 6: S4-20-S4-21. DOI: 10.1016/0924-977X(96)82878-1  0.376
1996 Roth B, Hamblin M, Sibley D, Meltzer H. Binding of atypical antipsychotic drugs to novel neurotransmitter receptors Schizophrenia Research. 18: 142. DOI: 10.1016/0920-9964(96)85467-3  0.307
1996 Kuroki T, Ichikawa J, Dai J, Meltzer H. Differential effects of typical and atypical antipsychotics on 5-HT release Biological Psychiatry. 39: 533-534. DOI: 10.1016/0006-3223(96)84066-2  0.304
1996 Fatemi SH, Meltzer HY, Roth BL. Atypical Antipsychotic Drugs: Clinical and Preclinical Studies Handbook of Experimental Pharmacology. 120: 77-115. DOI: 10.1007/978-3-642-61007-3_4  0.359
1995 Meltzer HY. Multiple-outcome criteria in schizophrenia: an overview of outcome with clozapine European Psychiatry. 10: 19. PMID 19698385 DOI: 10.1016/0767-399X(96)80080-0  0.361
1995 Meltzer HY, Hippius H. The assessment and management of treatment-resistant schizophrenia in perspective European Psychiatry. 10. PMID 19698381 DOI: 10.1016/0767-399X(96)80077-0  0.401
1995 Ichikawa J, Kuroki T, Kitchen MT, Meltzer HY. R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. European Journal of Pharmacology. 287: 179-84. PMID 8749033 DOI: 10.1016/0014-2999(95)00624-9  0.331
1995 Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology. 120: 365-8. PMID 8524985 DOI: 10.1007/Bf02311185  0.325
1995 Meltzer HY. Neuroleptic withdrawal in schizophrenic patients. An idea whose time has come. Archives of General Psychiatry. 52: 200-2. PMID 7872845 DOI: 10.1001/Archpsyc.1995.03950150032005  0.364
1995 Meltzer HY, Maes M. Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man. Psychopharmacology. 114: 635-43. PMID 7855226 DOI: 10.1007/Bf02244995  0.318
1995 Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. The American Journal of Psychiatry. 152: 183-90. PMID 7840350 DOI: 10.1176/Ajp.152.2.183  0.324
1995 Maes M, Meltzer HY, Buckley P, Bosmans E. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. European Archives of Psychiatry and Clinical Neuroscience. 244: 325-9. PMID 7772617 DOI: 10.1007/Bf02190412  0.34
1995 Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 12: 39-45. PMID 7766285 DOI: 10.1016/0893-133X(94)00060-D  0.375
1995 Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. Journal of Clinical Psychopharmacology. 15: 2S-3S. PMID 7730497 DOI: 10.1097/00004714-199502001-00001  0.404
1995 Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. Journal of Psychiatric Research. 29: 141-52. PMID 7666381 DOI: 10.1016/0022-3956(94)00049-W  0.326
1995 Elkis H, Friedman L, Wise A, Meltzer HY. Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia. Archives of General Psychiatry. 52: 735-46. PMID 7654125 DOI: 10.1001/Archpsyc.1995.03950210029008  0.354
1995 Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Research. 681: 109-16. PMID 7552267 DOI: 10.1016/0006-8993(95)00301-6  0.362
1995 Meltzer HY, Fatemi H. Suicide in Schizophrenia: The Effect of Clozapine Clinical Neuropharmacology. 18: S18-S24. DOI: 10.1097/00002826-199518003-00003  0.326
1995 Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D. Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease Neuropsychopharmacology. 12: 39-45. DOI: 10.1038/Sj.Npp.1380237  0.372
1995 Friedman L, Jesberger JA, Siever LJ, Thompson P, Mohs R, Meltzer HY. Smooth pursuit performance in patients with affective disorders or schizophrenia and normal controls: analysis with specific oculomotor measures, RMS error and qualitative ratings Psychological Medicine. 25: 387-403. DOI: 10.1017/S003329170003628X  0.334
1995 Bligh-Glover W, Jaskiw G, Vrtunski B, Ubogy D, Meltzer H. 5HT2-receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats Schizophrenia Research. 15: 153-154. DOI: 10.1016/0920-9964(95)95477-Q  0.31
1995 Elkis H, Friedman L, Thompson P, Maes M, Meltzer H. The concept of schizophrenia and the phenomenological models of kraepelin, bleuler and schneider: A confirmatory factor analysis Schizophrenia Research. 15: 11. DOI: 10.1016/0920-9964(95)95045-B  0.33
1994 Sajatovic M, Ramirez LF, Kenny JT, Meltzer HY. The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients. Comprehensive Psychiatry. 35: 29-33. PMID 8149726 DOI: 10.1016/0010-440X(94)90166-X  0.352
1994 Buckley P, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. The American Journal of Psychiatry. 151: 385-9. PMID 8109646 DOI: 10.1176/Ajp.151.3.385  0.35
1994 Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatrica Scandinavica. 89: 346-51. PMID 8067274 DOI: 10.1111/J.1600-0447.1994.Tb01527.X  0.327
1994 Gerson SL, Arce C, Meltzer HY. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. British Journal of Haematology. 86: 555-61. PMID 8043437 DOI: 10.1111/J.1365-2141.1994.Tb04786.X  0.315
1994 Arora RC, Meltzer HY. Effect of clozapine treatment on serotonin-2-receptor binding in the blood platelets of schizophrenic patients. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 10: 109-14. PMID 8024672 DOI: 10.1038/Npp.1994.12  0.351
1994 Meltzer HY. Serotonin2A receptors in schizophrenia: relation to suicide. Archives of General Psychiatry. 51: 1003-4. PMID 7979879 DOI: 10.1001/Archpsyc.1994.03950120075015  0.373
1994 Hasegawa M, Cola PA, Meltzer HY. Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 11: 45-7. PMID 7945743 DOI: 10.1038/Npp.1994.34  0.306
1994 Meltzer HY, Lee MA, Ranjan R. Recent advances in the pharmacotherapy of schizophrenia Acta Psychiatrica Scandinavica, Supplement. 384: 95-101. PMID 7533472 DOI: 10.1111/J.1600-0447.1994.Tb05897.X  0.38
1994 Meltzer H. Serotonin mechanisms in schizophrenia European Neuropsychopharmacology. 4: 197. DOI: 10.1016/0924-977X(94)90034-5  0.372
1993 Parsa MA, al-Lahham YH, Ramirez LF, Meltzer HY. Prolonged psychotic relapse after abrupt clozapine withdrawal. Journal of Clinical Psychopharmacology. 13: 154-5. PMID 8463447 DOI: 10.1097/00004714-199304000-00012  0.317
1993 Pehek EA, Meltzer HY, Yamamoto BK. The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. European Journal of Pharmacology. 240: 107-9. PMID 8405119 DOI: 10.1016/0014-2999(93)90555-V  0.354
1993 Parsa MA, Simon M, Dubrow C, Ramirez LF, Meltzer HY. Psychiatric manifestations of olivo-ponto-cerebellar atrophy and treatment with clozapine. International Journal of Psychiatry in Medicine. 23: 149-56. PMID 8359997 DOI: 10.2190/Pnr2-Pw5Y-Kf07-H5Be  0.306
1993 Arora RC, Meltzer HY. Serotonin2 receptor binding in blood platelets of schizophrenic patients. Psychiatry Research. 47: 111-9. PMID 8341764 DOI: 10.1016/0165-1781(93)90041-E  0.352
1993 Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. The American Journal of Psychiatry. 150: 1630-8. PMID 8105705 DOI: 10.1176/Ajp.150.11.1630  0.337
1993 Meltzer HY. Serotonin receptors and antipsychotic drug action. Psychopharmacology Series. 10: 70-81. PMID 8103227 DOI: 10.1007/978-3-642-78010-3_7  0.357
1993 Meltzer HY, Maes M, Lee MA. The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine Psychopharmacology. 112. PMID 7831446 DOI: 10.1007/Bf02245013  0.405
1993 Meltzer HY. Serotonin-Dopamine Interactions and Atypical Antipsychotic Drugs Psychiatric Annals. 23: 193-200. DOI: 10.3928/0048-5713-19930401-08  0.33
1993 HASEGAWA M, GUTIERREZ-ESTEINOU R, WAY L, MELTZER HY. Relationship Between Clinical Efficacy and Clozapine Concentrations in Plasma in Schizophrenia Journal of Clinical Psychopharmacology. 13: 383???390. DOI: 10.1097/00004714-199312000-00003  0.318
1993 Goyer P, Berridge M, Semple W, Morris E, Wong D, Schulz S, Miraldi F, Meltzer H. Dopamine-2 and serotonin-2 receptor indices in clozapine treated schizophrenic patients Schizophrenia Research. 9: 199. DOI: 10.1016/0920-9964(93)90416-G  0.362
1993 Buckley P, Friedman L, Lys C, Findling R, Meltzer H. Genetic and obstetrical determinants of cerebral morphology on computed tomography in schizophrenia Schizophrenia Research. 9: 195. DOI: 10.1016/0920-9964(93)90404-7  0.304
1993 Buckley P, Friedman L, Lys C, Elkis H, Meltzer H. Influences of age and gender on cerebral morphology on computed tomography in schizophrenia Schizophrenia Research. 9: 195. DOI: 10.1016/0920-9964(93)90403-6  0.302
1992 Lee HS, Meltzer HY. Buspirone does not produce a 5-HT1A-mediated decrease in temperature in man. Journal of Neural Transmission. General Section. 86: 71-6. PMID 1751030 DOI: 10.1007/Bf01250377  0.32
1992 Nerozzi D, Magnani A, Dastoli C, Ferri E, Capesciotti G, Antonozzi I, Frajese G, Meltzer HY. Prolactin responses to domperidone in chronic schizophrenia. Psychiatry Research. 42: 159-69. PMID 1631251 DOI: 10.1016/0165-1781(92)90079-I  0.369
1992 Lee HS, Bastani B, Friedman L, Ramirez L, Meltzer HY. Effect of the serotonin agonist, MK-212, on body temperature in schizophrenia. Biological Psychiatry. 31: 460-70. PMID 1581424 DOI: 10.1016/0006-3223(92)90258-2  0.36
1992 Meltzer HY, Hong SL, Nash JF. Effect of Buspirone on Prolactin Secretion Is Not Mediated by 5-HT-1a Receptor Stimulation Archives of General Psychiatry. 49: 163. PMID 1550467 DOI: 10.1001/Archpsyc.1992.01820020083011  0.331
1992 Friedman L, Abel LA, Jesberger JA, Malki A, Meltzer HY. Saccadic intrusions into smooth pursuit in patients with schizophrenia or affective disorder and normal controls. Biological Psychiatry. 31: 1110-8. PMID 1525275 DOI: 10.1016/0006-3223(92)90155-S  0.327
1992 Meltzer HY, Zhang Y, Stockmeier CA. Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action. European Journal of Pharmacology. 216: 67-71. PMID 1388121 DOI: 10.1016/0014-2999(92)90210-U  0.349
1992 Chai B, Meltzer HY. The effect of chronic clozapine on basal dopamine release and apomorphine-induced DA release in the striatum and nucleus accumbens as measured by in vivo brain microdialysis. Neuroscience Letters. 140: 47-50. PMID 1383891 DOI: 10.1016/0304-3940(92)90678-Z  0.303
1992 Ichikawa J, Meltzer HY. The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Research. 574: 98-104. PMID 1379112 DOI: 10.1016/0006-8993(92)90805-J  0.322
1992 Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin. 18: 515-42. PMID 1357741 DOI: 10.1093/Schbul/18.3.515  0.333
1992 Meltzer HY, Stockmeier CA. In vivo occupancy of dopamine receptors by antipsychotic drugs. Archives of General Psychiatry. 49: 588-9. PMID 1352678 DOI: 10.1001/Archpsyc.1992.01820070082019  0.37
1992 Ichikawa J, Meltzer HY. Amperozide, a novel antipsychotic drug, inhibits the ability of d-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens. Journal of Neurochemistry. 58: 2285-91. PMID 1349347 DOI: 10.1111/J.1471-4159.1992.Tb10975.X  0.31
1992 Friedman L, Jesberger JA, Meltzer HY. Effect of typical antipsychotic medications and clozapine on smooth pursuit performance in patients with schizophrenia. Psychiatry Research. 41: 25-36. PMID 1348583 DOI: 10.1016/0165-1781(92)90015-U  0.348
1992 Meltzer HY. The Importance of Serotonin-Dopamine Interactions in the Action of Clozapine British Journal of Psychiatry. 160: 22-29. DOI: 10.1192/S0007125000296876  0.358
1992 Kenny J, Meltzer H. Effect of atypical and typical antipsychotic drugs on neuropsychological functions in early-stage schizophrenic patients Schizophrenia Research. 6: 162. DOI: 10.1016/0920-9964(92)90254-3  0.31
1992 Lee F, Schulz SC, Lys C, Lee H, Meltzer H. VBR and adolescent onset of schizophrenia Schizophrenia Research. 6: 144-145. DOI: 10.1016/0920-9964(92)90212-N  0.319
1991 Nerozzi D, Magnani A, Sforza V, Scaramucci E, Cerilli M, Moretti C, Frajese G, Antonozzi I, Meltzer HY. Plasma prolactin response to domperidone in acute schizophrenia and schizophreniform illness. Psychiatry Research. 34: 139-47. PMID 2149613 DOI: 10.1016/0165-1781(90)90015-W  0.374
1991 Meltzer HY. Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin. 16: 563-5. PMID 2077634 DOI: 10.1093/Schbul/16.4.563  0.309
1991 Lee HS, Kwon KY, Alphs LD, Meltzer HY. Effect of clozapine on psychogenic polydipsia in chronic schizophrenia. Journal of Clinical Psychopharmacology. 11: 222-3. PMID 2066464 DOI: 10.1097/00004714-199106000-00022  0.354
1991 Friedman L, Knutson L, Shurell M, Meltzer HY. Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biological Psychiatry. 29: 865-77. PMID 2049485 DOI: 10.1016/0006-3223(91)90053-O  0.348
1991 Abel LA, Friedman L, Jesberger J, Malki A, Meltzer HY. Quantitative assessment of smooth pursuit gain and catch-up saccades in schizophrenia and affective disorders. Biological Psychiatry. 29: 1063-72. PMID 1873370 DOI: 10.1016/0006-3223(91)90248-K  0.314
1991 Lee MA, Nash JF, Barnes M, Meltzer HY. Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans. Psychopharmacology. 103: 258-64. PMID 1851310 DOI: 10.1007/Bf02244213  0.316
1991 Nash JF, Arora RC, Schreiber MA, Meltzer HY. Effect of 3,4-methylenedioxymethamphetamine on [3H]paroxetine binding in the frontal cortex and blood platelets of rats. Biochemical Pharmacology. 41: 79-84. PMID 1702633 DOI: 10.1016/0006-2952(91)90013-U  0.31
1991 Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophrenia Bulletin. 17: 263-87. PMID 1679253 DOI: 10.1093/Schbul/17.2.263  0.382
1991 Arora RC, Meltzer HY. Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. Journal of Neural Transmission. General Section. 85: 19-29. PMID 1678267 DOI: 10.1007/Bf01244654  0.36
1991 Sajatovic M, Verbanac P, Ramirez LF, Meltzer HY. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. Neurology. 41: 156. PMID 1670739 DOI: 10.1212/Wnl.41.1.156  0.32
1991 Bastani B, Arora RC, Meltzer HY. Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients Biological Psychiatry. 30: 131-139. PMID 1655071 DOI: 10.1016/0006-3223(91)90166-J  0.312
1991 Brockington I, Roper A, Buckley M, Copas J, Andrade C, Wigg P, Farmer A, Kaufman C, Hawley R, Meltzer H. Bipolar disorder, cycloid psychosis and schizophrenia: a study using “lifetime” psychopathology ratings, factor analysis and canonical variate analysis European Psychiatry. 6: 223-236. DOI: 10.1017/S0924933800003850  0.305
1991 Lowy M, Hu Q, Meltzer H. Chronic clozapine, but not typical antipsychotic agents, increase lymphocyte glucocorticoid receptors in schizophrenics Schizophrenia Research. 4: 351-352. DOI: 10.1016/0920-9964(91)90269-W  0.321
1991 Stockmeier C, Matsubara S, Zhang Y, Meltzer H. Effect of typical and atypical antipsychotic drugs on the in vivo binding of [3H]N-methyl-spiperone to serotonin-2 and dopamine-2 receptors in rat brain Schizophrenia Research. 4: 326-327. DOI: 10.1016/0920-9964(91)90227-I  0.329
1991 Pehek E, Yamamoto B, Meltzer H. The effects of clozapine on dopamine, 5-HT, and glutamate release in the rat medial prefrontal cortex Schizophrenia Research. 4: 323-324. DOI: 10.1016/0920-9964(91)90222-D  0.315
1991 Friedman L, Bastani B, Raimirez L, Knutson L, Shurell M, Meltzer H. Prefrontal sulcal prominence is inversely related to treatment response to clozapine in schizophrenia Schizophrenia Research. 4: 317. DOI: 10.1016/0920-9964(91)90210-I  0.366
1990 Bastani B, Nash JF, Meltzer HY. Prolactin and Cortisol Responses to MK-212, a Serotonin Agonist, in Obsessive-Compulsive Disorder Archives of General Psychiatry. 47: 833-839. PMID 2203327 DOI: 10.1001/Archpsyc.1990.01810210041006  0.345
1990 Nash JF, Meltzer HY, Gudelsky GA. Effect of 3,4-methylenedioxymethamphetamine on 3,4-dihydroxyphenylalanine accumulation in the striatum and nucleus accumbens. Journal of Neurochemistry. 54: 1062-7. PMID 1689375 DOI: 10.1111/J.1471-4159.1990.Tb02358.X  0.329
1990 Meltzer HY. The Role of Serotonin in the Action of Atypical Antipsychotic Drugs Psychiatric Annals. 20: 571-579. DOI: 10.3928/0048-5713-19901001-08  0.321
1990 Meltzer HY. Clozapine and Electroconvulsive Therapy-Reply Archives of General Psychiatry. 47: 291. DOI: 10.1001/Archpsyc.1990.01810150091019  0.31
1989 Meltzer HY. New insights into schizophrenia through atypical antipsychotic drugs. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 1: 193-6. PMID 2908017 DOI: 10.1016/0893-133X(88)90015-2  0.362
1989 Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. S18-27. PMID 2682729 DOI: 10.1007/Bf00442554  0.381
1989 Gudelsky GA, Nash JF, Berry SA, Meltzer HY. Basic biology of clozapine: electrophysiological and neuroendocrinological studies. Psychopharmacology. 99: S13-7. PMID 2682728 DOI: 10.1007/Bf00442553  0.378
1989 Meltzer HY, Zureick J. Negative symptoms in schizophrenia: a target for new drug development. Psychopharmacology Series. 7: 68-77. PMID 2574456 DOI: 10.1007/978-3-642-74430-3_8  0.38
1989 Meltzer HY, Koenig JI, Nash JF, Gudelsky GA. Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs. Acta Psychiatrica Scandinavica. Supplementum. 352: 24-9. PMID 2573238 DOI: 10.1111/J.1600-0447.1989.Tb06432.X  0.322
1989 Gudelsky GA, Meltzer HY. Activation of tuberoinfundibular dopamine neurons following the acute administration of atypical antipsychotics. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 2: 45-51. PMID 2572233 DOI: 10.1016/0893-133X(89)90006-7  0.318
1989 Matsubara S, Meltzer HY. Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex. Life Sciences. 45: 1397-406. PMID 2571912 DOI: 10.1016/0024-3205(89)90027-1  0.355
1989 Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Archives of General Psychiatry. 46: 672. PMID 2567591 DOI: 10.1001/Archpsyc.1989.01810070098017  0.321
1989 Nash JF, Meltzer HY, Gudelsky GA. Selective cross-tolerance to 5-HT1A and 5-HT2 receptor-mediated temperature and corticosterone responses. Pharmacology, Biochemistry, and Behavior. 33: 781-5. PMID 2533356 DOI: 10.1016/0091-3057(89)90470-X  0.332
1989 Lowy MT, Nash JF, Meltzer HY. Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA). European Journal of Pharmacology. 163: 157-61. PMID 2472965 DOI: 10.1016/0014-2999(89)90411-1  0.315
1989 Meltzer H. Serotonergic Dysfunction in Depression British Journal of Psychiatry. 155: 25-31. DOI: 10.1192/S0007125000291733  0.338
1989 Meltzer H. The role of serotonin in the mechanism of action of antipsychotic drugs: Does 5-HT also have a role in the etiology of schizophrenia? Schizophrenia Research. 2: 212. DOI: 10.1016/0920-9964(89)90248-X  0.374
1988 Lowy MT, Meltzer HY. Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist. Biological Psychiatry. 23: 818-28. PMID 3365458 DOI: 10.1016/0006-3223(88)90070-4  0.319
1988 Breslau N, Meltzer HY. Validity of subtyping psychotic depression: examination of phenomenology and demographic characteristics. The American Journal of Psychiatry. 145: 35-40. PMID 3337290 DOI: 10.1176/Ajp.145.1.35  0.314
1988 Lowy MT, Reder AT, Gormley GJ, Meltzer HY. Comparison of in vivo and in vitro glucocorticoid sensitivity in depression: relationship to the dexamethasone suppression test. Biological Psychiatry. 24: 619-30. PMID 3262379 DOI: 10.1016/0006-3223(88)90136-9  0.333
1988 Metz JT, Holcomb HH, Meltzer HY. Effect of 5-hydroxytryptophan on H-reflex recovery curves in normal subjects and patients with affective disorders. Biological Psychiatry. 23: 602-11. PMID 3128339 DOI: 10.1016/0006-3223(88)90007-8  0.329
1988 Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry. 45: 789-796. PMID 3046553 DOI: 10.1001/Archpsyc.1988.01800330013001  0.348
1988 Nash JF, Meltzer HY, Gudelsky GA. Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. European Journal of Pharmacology. 151: 463-9. PMID 2905661 DOI: 10.1016/0014-2999(88)90544-4  0.351
1988 Koenig JI, Meltzer HY, Gudelsky GA. 5-Hydroxytryptamine1A receptor-mediated effects of buspirone, gepirone and ipsapirone. Pharmacology, Biochemistry, and Behavior. 29: 711-5. PMID 2901112 DOI: 10.1016/0091-3057(88)90192-X  0.306
1988 Silverstein ML, McDonald C, Meltzer HY. Differential patterns of neuropsychological deficit in psychiatric disorders Journal of Clinical Psychology. 44: 412-415. DOI: 10.1002/1097-4679(198805)44:3<412::Aid-Jclp2270440316>3.0.Co;2-#  0.344
1987 Arora RC, Locascio JJ, Meltzer HY. 3H-imipramine binding in blood platelets of schizophrenic patients. Psychiatry Research. 19: 215-24. PMID 3797548 DOI: 10.1016/0165-1781(86)90100-9  0.3
1987 Arora RC, Meltzer HY. Effect of subchronic treatment with imipramine, chlorpromazine and the combination on 3H-imipramine binding in rat blood platelets and frontal cortex. Life Sciences. 39: 2289-96. PMID 3796194 DOI: 10.1016/0024-3205(86)90659-4  0.311
1987 Meltzer HY. Biological studies in schizophrenia. Schizophrenia Bulletin. 13: 77-111. PMID 3602940 DOI: 10.1093/Schbul/13.1.77  0.408
1987 Passaro EA, Meltzer HY, Gudelsky GA. Effects of acute and chronic dexamethasone treatment on stimulated prolactin secretion in the rat. Endocrine Research. 13: 173-82. PMID 3497800 DOI: 10.3109/07435808709023671  0.302
1987 Meltzer HY, Arora RC. Platelet markers of suicidality. Annals of the New York Academy of Sciences. 487: 271-80. PMID 3471162 DOI: 10.1111/J.1749-6632.1986.Tb27906.X  0.302
1987 Gudelsky GA, Koenig JI, Simonovic M, Koyama T, Ohmori T, Meltzer HY. Differential effects of haloperidol, clozapine, and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat. Journal of Neural Transmission. 68: 227-40. PMID 3104536 DOI: 10.1007/Bf02098500  0.341
1987 Gudelsky GA, Koenig JI, Meltzer HY. Selective desensitization of serotonin (5-HT) receptor-mediated hyperthermia by mianserin and other 5-HT antagonists. Neuropharmacology. 26: 707-12. PMID 2957607 DOI: 10.1016/0028-3908(87)90231-0  0.316
1987 Koenig JI, Gudelsky GA, Meltzer HY. Stimulation of corticosterone and beta-endorphin secretion in the rat by selective 5-HT receptor subtype activation. European Journal of Pharmacology. 137: 1-8. PMID 2956114 DOI: 10.1016/0014-2999(87)90175-0  0.307
1986 Gudelsky GA, Koenig JI, Meltzer HY. Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology. 25: 1307-13. PMID 2951611 DOI: 10.1016/0028-3908(86)90101-2  0.318
1986 Gudelsky GA, Koenig JI, Jackman H, Meltzer HY. Suppression of the hypo- and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors. Psychopharmacology. 90: 403-7. PMID 2947256 DOI: 10.1007/Bf00179199  0.333
1986 Andree TH, Mikuni M, Tong CY, Koenig JI, Meltzer HY. Differential effect of subchronic treatment with various neuroleptic agents on serotonin2 receptors in rat cerebral cortex. Journal of Neurochemistry. 46: 191-7. PMID 2866233 DOI: 10.1111/J.1471-4159.1986.Tb12944.X  0.34
1986 MELTZER HY, SOMMERS AA, LUCHINS DJ. The Effect of Neuroleptics and Other Psychotropic Drugs on Negative Symptoms in Schizophrenia Journal of Clinical Psychopharmacology. 6: 329???338. DOI: 10.1097/00004714-198612000-00002  0.364
Show low-probability matches.